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1 Zusammenfassung 
Die neoplastische Entartung erfolgt durch ein Zusammenspiel von genetischen und epigenetischen 
Veränderungen (wie CpG Hypermethylierungen von Promotern und Histon-Modifizierungen). 
Zusammengenommen führen diese Veränderungen zu genomischer Instabilität, zur Ausschaltung 
von Tumorsuppressorgenen und zur Aktivierung von Proto-Onkogenen. 
Hier zeigen wir, dass TIP5 (ein Protein mit Bromodomäne, das normalerweise zur epigenetischen 
Inaktivierung von rRNA Genen benötigt wird) in metastatischem Prostatakrebs (PKr) überexprimiert 
wird und Gene reguliert, die in metastatischen Prostatatumoren häufig supprimiert sind. 
Expressionslevel von TIP5 sind frühe prognostische Marker zur Unterscheidung von aggressivem 
und weniger aggressivem PKr. Anomale Geninaktivierung im PKr durch TIP5 entsteht unter Zutun 
von EZH2 (Bestandteil des Polycomb Repressive Complex 2). Diese H3K27-Methyltransferase wurde 
bereits als überexprimiert in PKr beschrieben, was mit schlechten Prognosen einher ging. Wir 
definieren ein Set von Genen, die von TIP5 und EZH2 supprimiert werden und in metatastischem 
PKr inaktiv sind (RTEM). Die Inaktivierung dieser Gene ist nicht auf PKr beschränkt, sondern kann 
auch in den Osteosarkomzellen U2OS nachgewiesen werden. Dies deutet darauf hin, dass 
epigenetische Veränderungen der RTEM Gene typisch für einen neoplastischen Phänotyp sind. Wir 
zeigen zudem, dass TIP5 durch ähnliche Mechanismen zu den RTEM Promotern gelangen könnte 
wie in gesunden Zellen zu den rRNA Genen. 
 
 
Schlüsselwörter: TIP5, EZH2, Prostatakrebs, Osteosarkom, Epigenetik 
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2 Summary 
Neoplastic transformation is driven by an alliance of genetic alterations and epigenetic abnormalities 
such as CpG hypermethylation of promoters and histone modifications. Collectively, these alterations 
promote genomic instability and lead to silencing of tumor-suppressor genes and activation of proto-
oncogenes.  
Here we show that TIP5, a bromo domain-containing protein normally required for epigenetic 
silencing of ribosomal RNA genes, is overexpressed in metastatic prostate cancer (PCa) tissue and 
regulates genes frequently repressed in prostate metastatic tumors. Expression levels of TIP5 serve as 
an early prognostic marker to distinguish indolent from aggressive PCa. Aberrant gene silencing in 
PCa cells mediated by TIP5 acts in cooperation with EZH2, a component of Polycomb repressive 
complex 2 and H3K27 methyltransferase, previously reported to be overexpressed in metastatic PCa 
and linked to poor prognosis. This study defines a set of genes repressed by TIP5 and EZH2 and 
silenced in metastatic PCa (RTEM). Repression of these genes is not only limited to PCa cells but also 
found in osteosarcoma U2OS cells, indicating that epigenetic alterations at RTEM genes are common 
to cancer phenotype. We also show that recruitment of TIP5 to RTEM promoters in cancer might 
share similar mechanisms to that one found for ribosomal RNA genes in healthy cells. 
 
 
Keywords: TIP5, EZH2, prostate cancer, osteosarcoma, epigenetic 
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3 Introduction 
Adapted and modified from my master thesis “Role of TIP5 in Metastatic Prostate Cancer Cells”. 
 
3.1 Chromatin structure 
Eukaryotic cells contain a nucleus in which the genomic DNA is organized in a complex structure 
called chromatin. The minimal and fundamental structural unit of chromatin is the nucleosome, 
comprised of ∼147 base pairs of DNA wrapped around a histone octamer core in a left-handed 
superhelix [1, 2]. The histone octamer is a protein complex composed of one histone H3-H4 tetramer 
that is flanked by two histone H2A-H2B dimers [2]. Except for their N-terminal tails, the core histones 
are predominantly globular. A linker DNA of variable length is located between two nucleosomes 
and bound by the linker histone H1 or in avian erythrocytes H5 [3].  
The nucleosomal array, a ‘beads-on-a-string’ fiber with a diameter of 11 nm, represents the next level 
of chromatin organization [2]. The binding of the linker histone organizes the nucleosome arrays into 
a more condensed 30 nm chromatin fiber that is also called “solenoid” [4]. Additional factors such as 
non-histone and nuclear scaffold proteins facilitate establishment of large chromatin loop domains 
that can be compacted further to generate interphase and mitotic chromosomes [5]. These different 
levels of chromatin structure are depicted and commented in Figure 1. Packing of eukaryotic 
genomes into high-order chromatin structures is critical for controlling processes derived from DNA 
like replication, transcription, recombination and repair. 
 
Chromatin is primarily organized in two different structural states: heterochromatin and euchromatin.  
The term heterochromatin was characterized in 1928 by Heitz who visualized chromosomal regions 
in moss that were deeply stained at prophase and remained compact throughout the mitotic cell cycle. 
([6] reviewed in [7, 8]). Fractions of the chromosome that were condensed at metaphase but diffuse 
and decondensed during interphase were referred to as euchromatin. Further studies revealed that 
heterochromatin is mainly located around centromeres and close to telomeres, is gene-poor, contains 
regular nucleosomal arrays of hypoacetylated histones and its transcription factor binding is limited 
(reviewed in [9]). On the other hand, euchromatin is gene-rich, contains irregular nucleosomal arrays, 
is associated with acetylated histones and is easily accessible to transcription factors. Also in term of 
replication euchromatin and heterochromatin are different: euchromatic DNA regions replicate in the 
early S-phase [10] while heterochromatin is replicated in late S-phase of the cell cycle (reviewed in 
[11]). 
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Figure 1 | Different levels of chromatin structure
Picture taken from Pierce, Benjamin. Genetics: A Conceptual Approach, 2nd ed. (New York: W. H. Freeman and
Company), 2005
3.2 Epigenetic regulation 
Cells of multicellular organisms contain essentially identical components of DNA though they are 
structurally and functionally heterogeneous. They differentiate to form distinct tissues and organs 
through differences in gene expression, based on environmental cues, cell-to-cell signals and other, 
probably random, factors. This variable transcriptional potential is a defining aspect of a cell’s 
identity and is mainly founded at the level of epigenetic signature and chromatin structure. 
Epigenetics is defined as changes in gene expression pattern heritable during cell division that are not 
caused by alterations of the DNA sequence, unlike mutations that are defined as a change of the 
nucleotide sequence. DNA methylation, histone modifications and non-coding RNAs are the 
predominant epigenetic mechanisms. Epigenetic mechanisms play an important role in gene 
regulation during development; one popular example is the transcriptional inactivation of one  
X-chromosome in female mammals. 
Research indicates long-term and wide-ranging effects of epigenetic on health. Diet and 
environmental exposures may potentially alter the level and scope of epigenetic regulation, thus 
interesting developments in the epigenomic research might explain correlations between lifestyle and 
risk of disease. Aberrant epigenetic patterns have been linked to a number of diseases including 
obesity, diabetes and cancer. Cancer was the first disease described to have altered epigenetic marks 
in the year 1983 (reviewed in [12]). Epigenetic modifications of DNA in cancer and precancerous 
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lesions give up hope of novel biomarkers for early cancer diagnosis, accurate prognosis, and efficient 
therapy. Furthermore, reversal of epigenetic changes is a potential target of novel therapeutic 
strategies and medication design. In the future, it is expectable that innovative diagnostic tests, drug 
regimens and even lifestyle modifications will be based on epigenetic mechanisms which will be 
incorporated into the practice of medicine. 
 
3.2.1 DNA methylation 
DNA methylation is one of the best-studied epigenetic mechanisms and a highly conserved 
epigenetic modification of DNA. Methylated cytosine has been found in the genome of organisms 
ranging from prokaryotes to mammals and is typically associated with gene silencing.  
In eukaryotic species, 5-Methylcytosine is found frequently within CpG dinucleotides. CpCs are 
distributed non-randomly in the genome and concentrated in genomic regions called CpG islands 
that are usually unmethylated. CpG methylation of promoters and enhancers is a mark of silent, 
inactive genes and associated with negative regulation of transcription. The transfer of a methyl 
group from S-adenosyl-methionine (SAM) to cytosine of CpG dinucleotides is catalyzed by DNA 
methyltransferases (DNMTs) (reviewed in [13]). Genome-wide cytosine methylation patterns are 
established during embryogenesis and are stably propagated throughout cell division by combined 
actions of DNMTs. DNA methylation is the only epigenetic mark which is not removed by the 
replication fork and serves consequently as a strong memory mark for inheritance of heterochromatin. 
 
DNMT1, DNMT3A and DNMT3B are the three enzymatically active DNMTs in mammalians and are 
divided into maintenance and de novo methyltransferases. DNMT1 is the primary maintenance 
methyltransferase and has a preference for hemimethylated CpG sites like those generated by DNA 
replication [14]. Its main function is to copy the methylation patterns during replication. DNMT3A 
and DNMT3B are essential for de novo methylation and responsible for the establishment of distinct 
methylation patterns during embryogenesis. Inactivation of the genes encoding these two 
methyltransferases blocks de novo methylation in ES cells and mouse embryos. Both 
methyltransferases are required for normal mammalian development but do not influence the 
maintenance of imprinted methylation patterns [15]. 
 
DNA methylation affects gene expression directly or indirectly. Several DNA binding proteins, for 
example transcription factors, can only interact with unmethylated DNA [16], whereas CpG 
methylation abolishes the interaction with their target sequences what leads to a lower transcription 
level. On the other hand, specific proteins, called MBD (methyl-CpG-binding domain) proteins, 
recognize CpG methylation and attract multiprotein complexes, which can change chromatin 
structure from open to close state. 
 
DNA methylation is essential for normal mammalian development [17] and involved in several 
fundamental processes, such as genomic imprinting, X chromosome inactivation and suppression of 
retrotransposon elements [18]. Although methylation patterns are largely maintained through 
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somatic cell divisions, changes in methylation patterns occur during mammalian development and 
cell differentiation. In addition to these changes, the DNA methylation pattern can alter in some adult 
somatic cells during aging and in pathologies such as cancer, causing aberrant repression of tumor 
suppressor genes through DNA hypermethylation of the CpG islands in promoters (reviewed in [19] 
and [20]). 
 
3.2.2 Histone modifications 
The core histones contain a globular C-terminal domain and highly dynamic N-terminal tail 
extending from the nucleosome. The N-terminal tail is enabled to experience different 
posttranslational modifications such as acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, ADP-ribosylation, deiminiation, proline isomerization, citrullination, butyrylation, 
propionylation and glycosylation (reviewed in [21] and [22]). All histone tails within the nucleosome 
can be multiple posttranslational modified and thereby induce a distinct chromatin signature and 
epigenetic profile. Most of the histone modifications are reversible and represent a fundamental 
regulatory mechanism for chromatin function [23]. They regulate key cellular processes such as 
transcription, replication and repair [21].  
 
Histone acetylation is a histone mark associated with transcriptional active state. The acetylation of 
lysines is highly dynamic and controlled by the opposing action of two families of enzymes. The 
histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine 
residues [24] what neutralizes lysine’s positive charge and weakens the interaction between histones 
and DNA and thus increases the accessibility of DNA to the transcription machinery. HATs 
opponents are the histone deacetylases (HDACs) that remove acetyl groups from histone lysines and 
restore the positive charge of the lysine what possibly stabilizes the local chromatin architecture 
(reviewed in [25]). HDACs contribute to transcriptional repression through chromatin compaction 
and are frequently associated with other transcriptional repressor proteins. 
 
Histone methylation takes place on N-terminal tails of histones H3 and H4 and mainly occurs on the 
side chains of lysines and arginines. Lysine methylation can occur as mono-, di- or tri-methylation 
while arginines may be mono-, symmetrically or asymmetrically di-methylated. Histone 
methyltransferases (HMTs) catalyze the transfer of a methyl group from SAM to lysine or arginine 
amino acids what has different effects to chromatin structure and transcription. Histone methylation 
does not alter the charge of the histones (reviewed in [25]). The two main silencing mechanisms in 
mammalian cells are tri-methylation of histone H3 lysine 9 (H3K9me3) and H3K27me3, where 
H3K9me3 mediates chromatin recruitment of heterochromatin protein 1 (HP1), heterochromatin 
condensation and gene silencing [26, 27]. H4K20 methylation is another chromatin repressing mark, 
however, lysine methylation is also associated with transcriptionally active genes. For instance 
methylation of H3K4, H3K36 and H3K79 are active histone marks. Recently, several histone 
demethylases were discovered. 
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Histone phosphorylation takes place on serines, threonine and tyrosines, predominantly on N-
terminal histone tails. The phosphorylation of histones is highly dynamic and controlled by the 
opposing action of two families of enzymes. Histone kinases transfer a phosphate group from ATP to 
the target amino acid what adds negative charge to the histone. The changes in charge influence the 
chromatin structure and suggest that histone phosphorylation has a similar function than acetylation 
in nucleosome dynamics (reviewed in [25]). The histone phosphatases are the opponents of the 
kinases and remove the phosphate group from the amino acid. 
 
All four core histones, as well as linker histone H1, are known to be mono–ADP ribosylated and 
poly–ADP ribosylated on glutamate and arginine residues [28]. The modification is reversible and 
performed by the poly(ADP-ribose) polymerase (PARP) family of enzymes. ADP ribosylation 
achieves a negative charge to the histone what is according with a more relaxed structure of poly-
ADP ribosylated chromatin [29]. This modification is removed by the poly-ADP-ribose-
glycohydrolase family of enzymes. 
 
Histone modifications are occurring in a variety of different combinations, each of those affect 
chromatin structure and gene transcription in their own way. Silent heterochromatin is a functional 
interaction of many epigenetic mechanisms including DNA methylation and a specific pattern of 
histone modifications such as low levels of acetylation and high levels of certain methylated lysine 
residues. 
 
3.3 Epigenetics of cancer cells 
Cancer develops through formation of distinct abilities such as sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion and metastasis. These so called hallmarks of cancer originate 
from aberrant gene function and altered patterns of gene expression. It is now clear that not only 
genetic alterations like mutation, copy number alteration, insertion, deletion, and recombination but 
also acquired epigenetic abnormalities contribute to cause this dysregulation [30]. Aberrant 
epigenetic mechanisms are manifest in both global changes in chromatin packaging and in localized 
gene promoter changes that influence the transcription of genes important to cancer progress [31, 32]. 
This implicates a central role of epigenetic processes in cancer causation, progression and treatment. 
In mammalian cells, a dynamic regulation of DNA CpG methylation, nucleosome remodeling and a 
set of acetylation, methylation and other modifications at histone amino acid residues is needed for 
proper DNA packaging to ensure the balance between transcriptional activation and repression. 
Although CpG methylation controls gene activity, it is insufficient to repress transcription by itself 
and the local chromatin structure also contributes in determining whether genes are transcribed or 
repressed. Increasing evidences indicate that there is a tight interdependence between DNA 
methylation and chromatin modifications for DNA packaging [33]. Consistent with this, DNMTs 
have been shown to interact with histone modifier enzymes (HDACs and HMTs), pointing to 
interdependence between silent epigenetic marks [34]. 
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3.3.1 DNA methylation and cancer 
Cancer cells undergo dramatic changes in the level and distribution of global DNA methylation 
pattern. Loss of DNA methylation and genomic instability is implicated in a variety of human cancers 
[35]; on the other hand, site-specific hypermethylation of CpG islands is a common mechanism used 
by tumor cells to silence tumor suppressor genes [31, 32]. Several genome-wide studies reported that 
a large number of promoter regions become de novo methylated in cancer [36, 37] and that most of 
these events occur at genes that are involved in growth selection (reviewed in [38]). Further, many 
studies confirmed that this de novo methylation is targeted and is predominantly specific for CpG 
islands marked with Polycomb repressor (reviewed in [38]) and some DNA methylation changes 
seem to be essential for cancer cell survival, indicating an acquired addiction to epigenetic alterations 
[39]. 
There is no question that abnormal methylation is important in tumorigenesis. Indeed, there are 
already therapies directed towards aberrant hypermethylation. Hypomethylating agents such as  
5-aza-2′deoxycytidine (Decitabine) and 5-azacytidine (Vidaza) are approved for the treatment of 
myelodysplastic syndromes [40] and clinical studies are also performed for solid tumors such as 
refractory advanced non-small cell lung cancer treated with combination of azacitidine and entinostat, 
inhibitors of DNA methylation and histone deacetylation [41]. 
 
3.3.2 Histone modifications and cancer 
In cancer, global alterations in histone acetylation appear including a global loss of acetylated H4K16 
[42] which results in gene repression. This loss of acetylation is mediated by HDACs whose 
overexpression is found in various types of cancer [43, 44]. To maintain histone acetylation levels 
HDACs collaborate with HATs which may be altered in cancer as well (reviewed in [45]). 
Further epigenetic alterations occurring in cancer are changes in histone methylation patterns. For 
example, chromosomal translocations of the trithorax homolog myeloid-lymphoid leukaemia (MLL), 
the H3K4 HMT, play a key role in leukemic progression by changing the pattern of the active histone 
mark H3K4 methylation, leading to ectopic expression of various homeotic (Hox) genes [46]. 
However, histone methylation marks leading to gene repression show irregular patterns in cancer as 
well. Besides DNA hypermethylation, cancer associated silenced gene promoters have diminished 
active marks like H3K9 acetylation and H3K4 methylation but enriched H3K9 and H3K27 
methylation, known to be associated with transcriptional repression [47].  
 
Indeed, there is already precedence for efficacious clinical application of therapies directed toward 
epigenetic mechanisms. Hypomethylating agents are approved for the treatment of myelodysplastic 
syndromes, and the histone deacetylase inhibitors vorinostat and romidepsin are approved for the 
treatment of cutaneous T-cell lymphoma [40]. 
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3.3.3 Polycomb group (PcG) proteins and cancer 
PcG proteins are epigenetic regulators that act via chromatin organization and play key roles in 
multiple aspects of cell physiology and identity, including regulation of all developmental genes, cell 
differentiation, stem and somatic cell reprogramming and response to environmental stimuli 
(reviewed in [48]). They form several multiprotein complexes where Polycomb Repressive Complex 1 
and 2 (PRC1 and PRC2) are the main complexes in mammals. 
The core of PRC1 includes one subunit of the PCGF, CBX, PHC, SCML and RING1 paralogous groups 
([49, 50] reviewed in [51]). PRC1 catalyzes the lysine 119 monoubiquitylation of H2A after binding of 
its chromodomain to H3K27me3 or independent of PRC2 (reviewed in [51]). 
PRC2 is composed of four core components: the histone methyltransferase enhancer of zeste 
homologue 1 (EZH1) or 2 (EZH2), EED, SUZ12 and RbAp46/48. EZH2 catalyzes di- and 
trimethylation of the lysine 27 residue of histone H3 (H3K27me2/3), this activity requires that EZH2 
is in complex with the other PRC2 components [52-55]. Trimethylation of H3K27 is a distinct histone 
modification involved in the regulation of Hox gene expression and in the early steps of  
X-chromosome inactivation in females [56]. This histone modification is associated with repressed 
chromatin states and genome-wide approaches revealed that H3K27me3 is widely distributed among 
genes encoding developmental regulators [19, 57-60]. 
 
Deregulation of PcG proteins has been observed in several types of cancer. BMI-1, belonging to PCGF 
group of PRC1, is overexpressed in squamous cell carcinomas, in neuroblastomas, in bladder tumors 
and in human medulloblastoma cell lines and primary tumors ([61], reviewed in [62]). Additionally, 
several studies describe its deregulation in leukemia (reviewed in [62]). Overexpression of EZH2 (part 
of PRC2) is found in various solid tumors including prostate, breast, bladder, colon, skin and lung 
cancer and is frequently positively correlated with aggressive disease and poor prognosis [63-66]. 
Various somatic mutations at Y641 in EZH2 were found in 7% of follicular lymphomas and in around 
20% of diffuse large cell B-cell lymphomas of germinal center origin [67] and showed altered catalytic 
activity of PRC2 increasing H3K27me in vitro [68].  
Recent results showed that genes repressed by PcG proteins in embryonic stem cells are marked by 
DNA hypermethylation in cancer, suggesting that PcG marks may be the main template for DNA 
methylation in cancer [58, 69, 70]. A biochemical study shows that EZH2 can interact with DNMTs 
and is responsible for de novo DNA methylation of CpG island genes in the osteosarcoma cell line 
U2OS [71]. This indicates a direct control of DNA methylation by EZH2, whereas this conflicts with a 
lack of DNA hypomethylation after knockdown of EZH2 in cancer cells [72]. However, the interaction 
between DNA methylation and the PcG proteins remains unclear. 
These studies imply that deregulation of PcG proteins and the appropriate histone methylation 
pattern are intimately associated with tumor initiation and development. 
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Figure 2 | Polycomb group proteins and cancer
A | Polycomb group (PcG) proteins like EZH2 transcriptionally repress tumour-­‐suppressor genes, which
normally prevent uncontrolled proliferation by cellular precautions such as apoptosis or senescence. B | The
involvement of PcG proteins in the maintenance and acquisition of pluripotency might also contribute to
cancer cell progression through the opportunity of gaining stem cell fate and unlimited proliferation.
 
3.4 Ribosomal RNA (rRNA) genes 
Ribosomal RNA (rRNA) genes are located in the well-defined nuclear compartment called nucleolus. 
In human, 400 rRNA gene copies are located in a non-uniform manner between the short arm and the 
satellite body of the five acrocentric chromosomes 13, 14, 15, 21 and 26, in a telomere-to-centromer 
orientation [73]. Mammalian rDNA transcription units are large, comprising approximately 43 kb nts 
in human and 45 kb nts in mice [74-76]. rDNA clusters are characterized by multiple alternating 
modules of a precursor rRNA sequence (pre-rRNA, approximately 13 kb) separated by long 
intergenic spacer sequences (IGS, approximately 30 kb). IGS contains elements important for the 
regulation of rDNA transcription, such as rDNA promoter, spacer promoter, repetitive enhancer 
elements and transcription termination sequences. Transcription of rRNA genes is performed by 
RNA polymerase I (Pol I) and a designated set of transcription factors as for instance upstream 
binding factor (UBF). It generates the 45S pre-rRNA precursor that is subsequently cleaved and 
processed into 28S, 18S and 5.8S rRNAs. These rRNAs are then packaged with ribosomal proteins to 
form the large and small subunits of ribosomes. 
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Ribosomes are macromolecular protein-RNA complexes required for translation of messenger RNA 
(mRNA) into proteins. Physiologically, ribosome production is associated with accurate cell growth 
and proliferation and regulated strictly throughout the cell cycle. In cancer cells, this regulation can 
be impaired, resulting in uncoupled protein synthesis from cell growth and proliferation and in the 
aberrant regulation of translation (reviewed in [77]). 
 
In proliferating cells, ribosomal gene transcription accounts for 35-60% of all cellular transcription 
and 80% of total RNA content [78]. Previous studies showed that not all the rRNA genes are 
competent for transcription [79, 80]. Distinct and specific epigenetic marks characterize active and 
silent rRNA genes (Figure 3). The promoter of active rRNA genes is free of CpG methylation and 
associated with histones that are acetylated. The opposite pattern is predominant among silent genes 
[81]. In addition, silent genes are associated with histones modified with repressive marks (H3K9me2, 
H4K20me3 and H3K27me3). To note is that the levels of active and silent rRNA gene chromatin is 
similar both in growing and resting cells as well as during interphase and metaphase, although their 
run-on activities differ significantly [79]. This result suggested that chromatin of active and silent 
rRNA genes is stably propagated throughout the cell cycle and maintained independently of 
transcriptional activity. This is also consistent with data showing that in mouse cells the epigenetic 
and chromatin state of a given CpG methylated silent rRNA gene is propagated to the daughter cells 
[82]. Moreover, studies in a HeLa cell line showed that Pol I, UBF and SL1 are always associated with 
the same nucleolar organizing regions (NORs), the chromosomal regions containing rRNA genes [83]. 
 
 
Figure 3 | Active and silent rRNA genes
Active rRNA genes (left panel) are associated with active histone marks and bound by UBF (upstream binding
factor) and SL1 (selectivity factor 1) to recruit Pol I (RNA polymerase I) and multiple Pol I-­‐associated factors
such as TIF-­‐IA (transcription initiation factor IA). Silent rRNA genes (right panel) are DNA methylated,
associated with silent histone marks and bound by NoRC consistent of TIP5 and SNF2H.
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3.4.1 Nucleolar remodeling complex (NoRC) 
The identification of the nucleolar remodeling complex NoRC was a gain of insights into the 
mechanisms that establish and propagate silent rDNA chromatin [81, 84, 85]. NoRC is composed of 
two subunits, the ATPase SNF2H and the 205 kDa protein TIP5 (TTF1 interacting protein 5) and is the 
key determinant that maintains individual rDNA repeats in a heterochromatic and silent state [81, 82, 
86]. The recruitment of NoRC to rDNA promoter is mediated by the interaction of TIP5 and TTF1, 
which is a transcription termination factor for Pol I and bound to the upstream terminator T0 
proximal of the rDNA promoter. Once bound to the promoter, NoRC represses rRNA transcription 
through recruitment of histone-modifying (HDAC, H3K9 and H3K27 HMTs, Poly(ADP-ribose) 
polymerase 1 (PARP1)) and DNA methylating enzymes (DNMT1 and 3b) [81, 84, 87]. The association 
of NoRC with rRNA genes takes place immediately after rDNA replication and its silencing activity is 
modulated by the association with a non-coding RNA originating from the intergenic rRNA region 
[82, 87, 88]. Taken together, NoRC coordinates epigenetic events that lead to transcriptional silencing 
and heterochromatin formation at the rDNA locus, linking “histone code”, “DNA methylation code” 
and “RNA world”. 
 
3.4.2 Ribosomal RNA genes and cancer 
The relationship between the nucleolus and cancer has been subject of studies for many years. 
Upregulation of ribosome production might contribute to neoplastic transformation by affecting the 
balance of protein translation, thus altering the synthesis of proteins that play an important role in the 
genesis of cancer [89]. The association in human carcinomas of nucleolar hypertrophy with bad 
prognosis is noteworthy. Abnormalities in the nucleolar morphology of cancer cells attracted the 
attention of tumor pathologists as early as the late 19th century. From that moment on, a series of 
studies have been performed to clarify whether these nucleolar changes were a consequence of the 
cancerous state or if, instead, they might represent a cause of neoplastic transformation. As cell 
proliferation appears to be closely coordinated with nucleolar function, nucleolar structural-
functional changes in tumors were considered as a mere consequence of both the proliferative activity 
of cancer cells and alterations of the mechanisms controlling cancer cell proliferation. In the last years 
some data have been produced that also suggest an active role of ribosome biogenesis in 
tumorigenesis. For example, human non-tumor lesions characterized by an upregulation of nucleolar 
function were found to be associated with an increased risk of neoplastic transformation. Evidence 
shows that people with inherited diseases characterized by the production of abnormal ribosomes 
have a very high incidence of cancer. 
Hypomethylation of the rRNA genes has been observed in several tumors like lung cancer, Wilms 
tumor and hepatocellular carcinomas [90-93]. Moreover, rDNA CpG methylation levels were found 
to be higher in ovarian cancer patients with long progression survival as compared with that in 
patients with short survival, an indication that rDNA silencing levels may influence cell growth 
properties essential for active tumor proliferation and tumor aggressiveness [91, 94]. Decreased CpG 
methylation of rRNA genes was found in many African–American women who suffer 
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disproportionately worse outcomes from endometrial cancer (even after controlling for 
socioeconomic factors and tumor stage/grade) [91]. These women possess notably lower rDNA 
methylation than non-African–American women. Consequently, it was proposed that rDNA 
methylation changes contribute in numerous ways to endometrial cancer and profiles of such 
alterations will likely be valuable for prognosis and therapeutic decision-making. To note, more 
aggressive type II endometrial cancer tumors possess significantly reduced levels of DNA 
methylation, as compared with the less aggressive type I endometrial cancers, possibly contributing 
to the type II endometrial cancer characteristic of genomic instability [95]. 
Taken together, all these studies suggested that controlling the CpG methylation state of rRNA genes 
might contribute to the aggressiveness of tumors. 
 
3.4.3 TIP5 and cancer 
Recent studies of our laboratory demonstrated that NIH3T3 cells depleted of TIP5 do not only display 
impairment of rRNA gene silencing but they undergo genomic instability. Knockdown of TIP5 
promotes higher rRNA synthesis and formation of enlarged nucleoli, a typical result of elevated 
nucleolar activities [87]. Consistent with this, depletion of TIP5 and consequent impairment of rDNA 
silencing promoted ribosome synthesis and enhanced the productivity of recombinant proteins in 
NIH3T3, CHO and HEK293T cells [96]. Importantly, these cells did not only proliferate at higher rates 
but they also grew beyond confluence and displayed a transformed phenotype. Surprisingly, 
upregulation of rRNA transcription in TIP5-depleted cells does not depend on the de-repression of 
silent genes. Whereas the amount of CpG methylated silent genes decreases in these cells, the number 
of active genes is not affected. Therefore, it seems that TIP5 and (or) presence of heterochromatic 
silent repeats indirectly affect(s) the transcription rate of active genes, probably by enriching the 
nucleolar compartment of the chromatin repressor complexes. However, it cannot be excluded that 
upregulation of rDNA transcription is a consequence of genome instability that caused the 
acquisition of aberrant mechanisms of rDNA transcriptional regulation, thus representing an 
advantage for the elevated protein synthesis necessary for high proliferative rates. 
Recently, a screen was performed to identify genes required for Ras-mediated epigenetic silencing of 
the pre-apoptotic Fas gene in K-ras-transformed NIH3T3 cells [97]. These results demonstrated the 
existence of a group of Ras epigenetic silencing effectors (RESEs) responsible for Ras-mediated 
epigenetic silencing of Fas. These RESEs included transcriptional regulators, DNA binding proteins, 
proteins involved in histone and DNA modifications (DOT1L, SMYD1, HDAC9 and DNMT1), several 
PcG proteins (BMI-1, EED and EZH2) and TIP5. The results described in Gazin et al. (2007) showed 
that depletion of TIP5 in K-ras-transformed NIH3T3 cells impairs DNA methylation of the Fas, Sfrp1 
and Plagl1 genes. Moreover, the levels of TIP5 and the other RESEs proteins were upregulated in  
K-ras-transformed cells. Importantly, knockdown of TIP5 markedly inhibited anchorage-independent 
growth and tumor growth of the transformed cells. These results indicated that TIP5 together with 
PcG proteins is involved in the “elaborate” pathway for Ras-mediated epigenetic silencing. 
Interestingly, putative TIP5 deregulation has been implicated in a paediatric case of pre-B acute 
lymphoblastic leukemia (ALL) in which a cryptic rearrangement between chromosome 12p13 and 
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12q13 generated a fusion of E-twenty six translocation variant (ETV) with an intronic sequence of 
TIP5 [98]. The authors do acknowledge, however, that the leukaemogenic impact of putative TIP5 
deregulation remains undetermined at present. An additional study proposed TIP5 as an eventual 
biomarker for early diagnosis of osteosarcoma since the expression levels of TIP5 were higher in three 
osteosarcoma cell lines (U2OS, MG-63, Saos-2) than in the osteoblastic cell line hFOB1.19 [99]. TIP5 
was found abundantly expressed in ovarian cancer cell lines including OVCAR3, A2780, ES2, and 
MPSC1, whereas its expression levels were relatively low in the OSE4 cell line that was derived from 
normal ovarian surface epithelium [100]. A recent study underlines the role of miR-let7c, miR-100, 
and miR-218 that are less expressed in metastatic prostate carcinoma. The authors proposed a role of 
these miRNA in the process of metastasization of prostate carcinoma and in controlling the 
expression of RAS, MYC, Laminin 5-β3, THAP2, SMARCA5, and TIP5 [101]. Taken together, these 
studies suggest that deregulation of TIP5 may have an impact on tumor development. 
 
3.5 Aim of the thesis 
The aim of this work is to determine whether: 
- TIP5 plays a role in the epigenetic gene silencing process in metastatic prostate cancer cells 
- This process is mediated by the association of TIP5 with EZH2 
- TIP5 plays a similar role in osteosarcoma cells 
- TTF1 recruits TIP5 to other gene promoters as described for rRNA genes 
 
To test these working hypotheses, the following experimental strategies were performed: 
- Examination of the microarray results of PC3 cells depleted of TIP5 and EZH2 by siRNA 
technology 
- Analysis of gene expression profiles of prostate cancer tumors that are benign, clinically 
localized or metastatic and refractory to hormones 
- Establishment of TIP5 and EZH2 siRNA knockdown in osteosarcoma cell line U2OS to 
analyze epigenetics and transcription of genes found repressed by TIP5 and EZH2 in 
metastatic prostate cancer cells PC3 and repressed in prostate metastatic tissues 
- Identification of genes that are bound by TIP5, EZH2 and TTF1 in U2OS cells 
- Investigate the association of TIP5 with EZH2 in PC3 cells 
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4 Material and methods 
Adapted and modified from my master thesis “Role of TIP5 in Metastatic Prostate Cancer Cells”. 
 
4.1 Material 
4.1.1 Cell lines 
Name Origin 
HEK293T Human Embryonic Kidney 
PC3 Human Prostate Carcinoma (Bone Metastasis) 
U2OS Human Osteosarcoma 
 
4.1.2 Media 
Name Company 
DMEM PAA 
Ham’s F-12 PAA 
RPMI 1640 PAA 
Opti-MEM Gibco® Invitrogen 
 
4.1.3 Buffers and solutions 
Name Composition 
1x PBS buffer 140 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
pH 7.4 
PBS-T buffer 1x PBS-buffer 
0,1% Tween-20 
2x BES 50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 6.96 or 7.0 
1x TAE buffer 40 mM Tris-acetate 
1 mM EDTA 
Chromatin Extraction buffer 200 mM NaCl 
10 mM HEPES 
10 mM MgCl2 
0.5% Triton X-100 
Hypotonic buffer 0.5% NP-40 
85 mM KCl 
5 mM HEPES (pH 7.4) 
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Nuclear extraction (NE) buffer 50 mM Tris-HCl (pH 7.5) 
150 mM KCl 
5. mM MgCl2 
0.2 mM EDTA 
20% Glycerol 
Add prior to use: 
1x Proteinase Inhibitor cocktail 
0.5 mM DTT 
0.1% NP-40 
Washing buffer 20 mM Tris-HCl (pH 7.5) 
100 mM KCl 
5 mM MgCl2 
0.2 mM EDTA 
10% Glycerol 
0.1% Tween-20 
Add prior to use: 
1x Proteinase Inhibitor cocktail 
10x Running buffer  1% SDS 
250 mM Tris 
1.92 M Glycine 
Laemmli buffer 2% SDS 
10% Glycerol 
100 mM DTT 
60 mM Tris-HCl, pH 6.8 
0.001% Bromphenol blue 
Blocking solution 1x PBS-T 
5% milk 
10x Transfer buffer 250 mM Tris 
1.92 M Glycine 
1x Transfer buffer 10x Transfer buffer 
20% Methanol 
0.01% SDS 
Buffer A 100 mM Tris-HCl, pH 8 
10 mM DTT 
Buffer B 10 mM EDTA 
10 mM HEPES 
10 mM EGTA 
0.25% Triton X-100 
Buffer C 10 mM EDTA 
10 mM HEPES 
0.5 mM EGTA 
200 mM NaCl 
Buffer D 1% SDS 
50 mM Tris-HCl, pH 8 
10 mM EDTA 
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ChIP buffer 16.7 mM Tris-HCl, pH 8 
16.7 mM NaCl 
1.2 mM EDTA 
0.01% SDS 
1.1% Triton X-100 
Elution buffer 1% SDS 
100 mM NaHCO3 
Wash buffer 1 0.1% SDS 
0.167 mM NaCl 
16.7 mM Tris-HCl, pH 8 
1% Triton X-100 
Wash buffer 2 0.1% SDS 
16.7 mM Tris-HCl, pH 8 
0.5 mM NaCl 
1% Triton X-100 
LiCl wash buffer 0.25 mM LiCl 
0.5% Na-deoxycholate 
0.5% NP40 
1 mM EDTA 
10 mM Tris-HCl, pH 8 
TE buffer 10 mM Tris-HCl, pH 8 
5 mM EDTA 
 
4.1.4 Chemicals, enzymes, reagents and kits 
Name Company Further Information 
Acrylamide SERVA 40% Acrylamide/Bis solution 
Agarose Promega Corporation  
Agarose beads MILLIPORE Protein A or G agarose/Salmon Sperm 
DNA, 50% slurry 
Ammonium persulfate SIGMA-ALDRICH  
Anti-FLAG M2 beads SIGMA-ALDRICH ANTI-FLAG M2 Affinity Gel A2220 
BES SIGMA-ALDRICH Bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid 
Bradford reagent BIO-RAD laboratories 
GmBH 
BIO-RAD Protein Assay 
Chloroform SIGMA-ALDRICH  
Coomassie blue Fluka Coomassie Brilliant Bue R 250 
DMSO SIGMA-ALDRICH Dimethyl sulfoxide 
DNase I Thermo Scientific  
dNTPs Fermentas dATP, dCTP, dGTP and dTTP; 100mM 
DTT SIGMA-ALDRICH DL-Dithiothreitol 
EDTA SIGMA-ALDRICH Ethylenediaminetetraacetic acid 
EGTA SIGMA-ALDRICH Ethylene glycol-bis(2-aminoethylether)-
tetraacetic acid 
Ethanol MERCK Absolute for analysis 
FBS Gibco® Invitrogen Fetal bovine serum 
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Formaldehyde SIGMA-ALDRICH Formaldehyde solution, 36.5% 
Glycin Roche  
Glycine BIOSOLVE  
Glycogen Roche  
HCl MERCK MILLIPORE 32% for analysis 
HEPES BIOSOLVE 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
Isopropanol MERCK  
KCl SIGMA-ALDRICH  
Lipofectamine® RNAiMAX Invitrogen  
Lithiumchlorid AppliChem GmbH  
Magnetic beads Invitrogen Dynabeads® Protein A or G 
Methanol MERCK  
MgCl2 Applied Biosystems, 
Roche 
TaqMan®, 25mM 
Milk Migros Rapilait, milk powder 
MultiScribeTM Reverse 
Transcriptase 
Applied Biosystems, 
Roche 
TaqMan®, MuLV, 50 U/µl 
NaCl SIGMA-ALDRICH  
NP-40 Fluka Nonidet P 40 Substitute 
NucleoSpin RNA II Kit Machery-Nagel  
Penicillin/Streptomycin Gibco® Invitrogen 10’000 U/ml Penicillin, 10’000 µg/ml 
Streptomycin 
Phenol chloroform SIGMA-ALDRICH Phenol:Chloroform:Isoamyl aclohol 
Polybrene SIGMA-ALDRICH 20 mg/ml 
Ponceau S SIGMA-ALDRICH  
Primer random p(dN)6 Roche 2 µg/µl 
Protease Inhibitor cocktail Roche Complete, EDTA-free 
Proteinase K Fermentas 21.2 mg/ml 
PVDF membrane MILLIPORE Immobilon®-FL 
RNase A Fermentas DNase and protease-free, 10 mg/ml 
Rnase Inhibitor Applied Biosystems, 
Roche 
TaqMan®, 20 U/µl 
RT Buffer 10x Applied Biosystems, 
Roche 
TaqMan® 
SDS SIGMA-ALDRICH Sodium dodecyl sulfate 
SYBR GREEN master mix BIOLINE 2x SensiMixTM SYBR Kit 
TEMED SIGMA-ALDRICH Tetramethylethylenediamine 
Tris BIOSOLVE Tris(hydroxymethyl)aminomethane 
Triton® X-100 SIGMA-ALDRICH  
TRIzol Reagent Invitrogen  
Trypsin-EDTA Gibco® Invitrogen 10x, 5% Trypsin 
Tween® 20 SIGMA  
X-tremeGene HP DNA 
Transfection Reagent 
Roche  
β-mercaptoethanol SIGMA-ALDRICH 2-Mercatpo-ethanol 
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4.1.5 Equipment 
Name Company Further Information 
Cell Counter INNOVATIS Casy® 
Fluorescence microscope Leica Microsystems Leica DMI6000 B 
NanoDrop® NanoDrop technologies, 
Thermo Scientific 
ND-1000, Spectrophotometer 
Odyssey scanner LI-COR Biosciences Two channel infrared detection 
PCR machine Applied Biosystems GeneAmp® PCR System 2700 
Protein separating device BIO-RAD Mini-PROTEAN Tetra Cell 
Protein wet transfer device BIO-RAD Mini Trans-Blot Cell 
qPCR machine Corbett Research Rotor-Gene RG-3000 A 
Sonifier Diagenode BIORUPTOR® 
Spectrophotometer Thermo Spectronic GENESYS 10uv 
 
4.1.6 Antibodies 
Antibodies IgG Origin Application 
Anti-TIP5 Zürich Rabbit Raffaella Santoro ChIP, Western Blot 
Anti-EZH2 Mouse BD Transduction Laboratories ChIP 
Anti-EZH2 Mouse Cell Signaling Technology Western Blot 
Anti-HA Mouse Santa Cruz Biotechnology Western Blot 
Anti-HA Rabbit Santa Cruz Biotechnology Western Blot 
Anti-PARP1 Rabbit Santa Cruz Biotechnology Western Blot 
Anti-PARP1 Mouse Santa Cruz Biotechnology Western Blot 
Anti-SNF2H Rabbit Santa Crus Biotechnology Western Blot 
Anti-TTF1 Rabbit Raffaella Santoro ChIP 
Anti-UBF Mouse Santa Cruz Biotechnology Western Blot 
Anti-Rabbit Goat Li-Cor Western Blot 
Anti-Mouse Goat Li-Cor Western Blot 
 
4.1.7 Oligonucleotides 
Name siRNA Target Sequence Qiagen Productname 
siRNA-CTRL not available AllStars Negative Control siRNA 
siRNA-TIP5 5’-CACTGAGAAGGCTAAGACTAA-3’ Hs_BAZ2A_4 
siRNA-EZH2 not available Hs_EZH2_7 
 
Primer Nucleotide Sequence Description 
ORS57 5’-TACTTGTGGAGCCGCTGAC-3’ Forward oligo hybridizing to the 
cDNA of human EZH2 mRNA. 
ORS58 5’-CTGCCACGTCAGATGGTG-3’ Reverse oligo hybridizing to the 
cDNA of human EZH2 mRNA. 
ORS111 5’-TGGACGATGTGCTCTATGCC-3’ Forward oligo hybridizing to the 
cDNA of human DAB2IP mRNA. 
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ORS112 5’-GGATGGTGATGGTTTGGTAG-3’ Reverse oligo hybridizing to the 
cDNA of human DAB2IP mRNA. 
ORS168 5’-TTCCTCTTTGCATGGAATTTG-3’ Forward oligo hybridizing to the 
cDNA of human ADRB2 mRNA. 
ORS169 5’-AGAGGAGTGGGGGAAGAGTC-3’ Reverse oligo hybridizing to the 
cDNA of human ADRB2 mRNA. 
ORS170 5’-TGCACCACCAACTGCTTAGC-3’ Forward oligo hybridizing to the 
cDNA of human GAPDH mRNA. 
ORS171 5’-GGCATGGACTGTGGTCATGAG-3’ Reverse oligo hybridizing to the 
cDNA of human GAPDH mRNA. 
ORS181 5’-CGAGCCCCTAGCACCCGACA-3’ Forward oligo hybridizing to the 
human ADRB2 gene at positions -
171 to -152. 
ORS182 5’-GGTCCGGCGCATGGCTTCTA-3’ Reverse oligo hybridizing to the 
human ADRB2 gene at positions +45 
to +64. 
ORS184 5’-CAACCGTCCCGGCGTCTTCC-3’ Forward oligo hybridizing to the 
human DAB2IP gene at positions -
225 to -204. 
ORS185 5’-CCCCTTTCCAGCCCTCGCCT-3’ Reverse oligo hybridizing to the 
human DAB2IP gene at positions -96 
to -77. 
ORS214 5’-TCGGCCTGAGACACCGGAGG-3' Forward oligo hybridizing to the 
cDNA of human MKX mRNA. 
ORS215 5’-CGTCATCTGCGAGCCGAGGG-3’ Reverse oligo hybridizing to the 
cDNA of human MKX mRNA. 
ORS216 5’-TTGACGCAGAGCGCAGCCAA-3’ Forward oligo hybridizing to the 
cDNA of human HOMER2 mRNA. 
ORS217 5’-TGCAGTGCTGTGGTCAGCCG-3’ Reverse oligo hybridizing to the 
cDNA of human HOMER2 mRNA. 
ORS218 5`-CCGACAAGCCCAGCGACAGG-3’ Forward oligo hybridizing to the 
cDNA of human AOX1 mRNA. 
ORS219 5`-GTGGCTGGACCAACGCCTCC-3’ Reverse oligo hybridizing to the 
cDNA of human AOX1 mRNA. 
ORS220 5`-GCTTGTGGCCCTGAGGCTGG-3’ Forward oligo hybridizing to the 
cDNA of human LAMB3 mRNA. 
ORS221 5`-TGGGCATTGAAGCCCCGCAG-3’ Reverse oligo hybridizing to the 
cDNA of human LAMB3 mRNA. 
ORS222 5`-AGCAGCCCCAGCGGATCTGA-3’ Forward oligo hybridizing to the 
cDNA of human ZNF185 mRNA. 
ORS223 5`-GTCCTGCCAGGCCTCTCCGA-3’ Reverse oligo hybridizing to the 
cDNA of human ZNF185 mRNA. 
ORS226 5`-GCCTCAACACCCGTGGGAGC-3’ Forward oligo hybridizing to the 
cDNA of human FBN1 mRNA. 
ORS227 5`-GCACTCGTCCTGGTTGGGGC-3’ Reverse oligo hybridizing to the 
cDNA of human FBN1 mRNA. 
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ORS228 5`-CCCATCACCACGGGAGGGGT-3’ Forward oligo hybridizing to the 
cDNA of human FHL2 mRNA. 
ORS229 5`-CTGTGAGGAAGCCACGCCCC-3’ Reverse oligo hybridizing to the 
cDNA of human FHL2 mRNA. 
ORS230 5`-CCTACGGCAACCTGCCCTGC-3’ Forward oligo hybridizing to the 
cDNA of human HOXA7 mRNA. 
ORS231 5`-GCGCCTTTGGCGAGGTCACT-3’ Reverse oligo hybridizing to the 
cDNA of human HOXA7 mRNA. 
ORS232 5`-ACCTCCGACCCCATTGGCGA-3’ Forward oligo hybridizing to the 
cDNA of human KLF6 mRNA. 
ORS233 5`-AAGTCCCGCTGCGCACCTTC-3’ Reverse oligo hybridizing to the 
cDNA of human KLF6 mRNA. 
ORS244 5`-AGGGCTAGTGTGCTCTAGGGGT-3` Forward oligo hybridizing to the 
human LAMB3 gene. 
ORS245 5`-TGGGGTGATCCCCAGAAAGGACC-3` Reverse oligo hybridizing to the 
human LAMB3 gene. 
ORS244 Z 5’-CAACGCTTGCCACCCCCGAT-3’ Forward oligo hybridizing to the 
human ZNF185 gene. 
ORS245 Z 5’-TTGGTGCGGCCTCCAAGAGC-3’ Reverse oligo hybridizing to the 
human ZNF185 gene. 
ORS250 5`-AGGTTGCTGAAAAGCCAGGAGTCA-3` Forward oligo hybridizing to the 
human FHL2 gene. 
ORS251 5`-AAGAGAGATTCGTTGCAATGGTGGC-3’ Reverse oligo hybridizing to the 
human FHL2 gene. 
ORS252 5`-CCTGTGAGGACTGCTGAGATTG-3` Forward oligo hybridizing to the 
human HOXA7 gene 
ORS253 5`-CCCCCAGATTTACACCAAACC-3` Reverse oligo hybridizing to the 
human HOXA7 gene. 
ORS254 5`-CCACAAAAAGTGTGTCGGCTTCGAG-3` 
 
Forward oligo hybridizing to the 
human HOXB8 gene 
ORS255 5`-TTCGCCGGCTCCTAGTCACCC-3` 
 
Reverse oligo hybridizing to the 
human HOXB8 gene. 
ORS260 5’-GAACCAGCGCGGACACCACA-3’ Forward oligo hybridizing to the 
human AOX1 gene. 
ORS261 5’-GCTCACCTTGCGGCCGTTCA-3’ Reverse oligo hybridizing to the 
human AOX1 gene. 
ORS262 5`-GCGCTCCGGGGAGACTTTCG-3` Forward oligo hybridizing to the 
human KLF6 gene. 
ORS263 5`-GGGAGCACGTCCATGTCGGG-3` Reverse oligo hybridizing to the 
human KLF6 gene. 
ORS317 5’-TACTAGCGGTTTTACGGGCG-3’ Forward oligo hybridizing to the 
human GAPDH gene. 
ORS318 5’-TCGAACAGGAGGAGCAGAGAGCG-3’ Reverse oligo hybridizing to the 
human GAPDH gene. 
ORS339 5’-GCACATGGAGCCAATATGCG-3’ Forward oligo hybridizing to the 
cDNA of human MYT1 mRNA. 
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ORS340 5’-GAGGGAGGTAAACGGTGTGG-3’ Reverse oligo hybridizing to the 
cDNA of human MYT1 mRNA. 
ORS347 5’-CCACTCCAAGCTCCTAAGGG-3’ Forward oligo hybridizing to the 
cDNA of human KCNA1 mRNA. 
ORS348 5’-CTCTCCAGTTCCCTTCGCTC-3’ Reverse oligo hybridizing to the 
cDNA of human KCNA1 mRNA. 
ORS349 5’-GATGACTGCGGGAGACAACC-3’ Forward oligo hybridizing to the 
cDNA of human CNR1 mRNA. 
ORS350 5’-AGTTCTCCCCACACTGGATG-3’ Reverse oligo hybridizing to the 
cDNA of human CNR1 mRNA. 
ORS361 5’-CAGGAAGACACCTCTCACAC-3’ Forward oligo hybridizing to the 
cDNA of human MYT1 mRNA. 
ORS362 5’-ACAGTGTCCAGGGGCTTTGC-3’ Reverse oligo hybridizing to the 
cDNA of human MYT1 mRNA. 
ORS363 5’-ATCTGGCACCACACCTTCTACA-3’ Forward oligo hybridizing to the 
cDNA of human β-ACTIN mRNA. 
ORS364 5’-TCACCGGAGTCCATCACGAT-3’ Reverse oligo hybridizing to the 
cDNA of human β-ACTIN mRNA. 
Hottiger 
711 F 
5’-CCTCACCCTCCAACAAAGAT-3’ Forward oligo hybridizing to the 
human IL6 gene. 
Hottiger 
712 R 
5’-GCCTCAGACATCTCCAGTCC-3’ Reverse oligo hybridizing to the 
human IL6 gene. 
hrDNA  
-150 
5’-CGATGGTGGCGTTTTTGG-3’ Forward oligo hybridizing to the 
human rRNA promoter at positions -
150 to -132. 
hrDNA 
+9/+21 
5’-GACAGGTCGCCAGAGGACAGC-3’ Reverse oligo hybridizing to the 
human rRNA gene at positions +9 to 
+21. 
hrDNA 
+502/19 
5’-CGTCCTTCTCGCTCCGCC-3’ Forward oligo hybridizing to the 
human rDNA at positions +502 to 
+519 used for 45S pre-rRNA 
amplification. 
hrDNA 
+705/687 
5’-GTGGTTGTCGACTTGCGGG-3’ Reverse oligo hybridizing to the 
human rDNA at positions +687 to 
+705 used for 45S pre-rRNA 
amplification. 
mhTIP5 
625–644 F 
5’-AAGATGTGTGGCTACAATGG-3’ Forward oligo hybridizing to the 
mouse and human TIP5 gene at 
positions +625 to +644 used for 
cDNA amplification. 
mhTIP5 
842–860 R 
5’-TCTGCACCCATCAGCTCCG-3’ Reverse oligo hybridizing to the 
mouse and human TIP5 gene at 
positions +842 to +860 used for 
cDNA amplification. 
mh28S F 
+8124 
5’-GCGACCTCAGATCAGACGTGG-3’ 
 
Forward oligo hybridizing to the 
mouse and human 28S rRNA. 
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mh28S R 
+8246 
5’-CTGTTCACTCGCCGTTACTGAG-3’ 
 
Reverse oligo hybridizing to the 
mouse and human 28S rRNA. 
H4 F 5’-CGACGACCCATTCGAACGTCT-3’ Forward oligo hybridizing to the 
human rDNA coding region at 
positions +3990 to +4010. 
H4 R 5’-CTCTCCGGAATCGAACCCTGA-3’ Reverse oligo hybridizing to the 
human rDNA coding region at 
positions +4072 to +4092. 
MYT1 F 5’-AGGCACCTTCTGTTGGCCGA-3’ Forward oligo hybridizing to the 
human MYT1 gene at positions -550 
to -530. 
MYT1 R 5’-AGGCAGCTGCCTCCCGTACA-3’ Reverse oligo hybridizing to the 
human MYT1 gene at positions -220 
to -201. 
KCNA1 F 5’-TGACGGTGATGTCTGGGGAG-3’ Forward oligo hybridizing to the 
human KCNA1 gene at positions 
+1107 to +1126. 
KCNA1 R 5’-GGTTGCGGTCGAAGAAGTAC-3’ Reverse oligo hybridizing to the 
human KCNA1 gene at positions 
+1342 to +1361. 
CNR1 F 5’-GCAGAGCTCTCCGTAGTCAG-3’ Forward oligo hybridizing to the 
human CNR1 gene. 
CNR1 R 5’-AACAGGCTGGGGCCATACAG-3’ Reverse oligo hybridizing to the 
human CNR1 gene. 
 
4.2 Cell culture methods 
4.2.1 Cell culture 
HEK293T and U2OS cells were cultured in DMEM containing stable glutamine. PC3 cells were 
cultured in RPMI and Ham’s F-12 (1:1). Both media were supplemented with 10% fetal calf serum and 
1% Penicillin/Streptomycin. Cells were grown at 37 °C with 5% CO2 in humid environment.  
To trypsinize cells, plates containing adherent cells were washed with 1x PBS (HEK293T: once; U2OS 
and PC3: three times) and then 1x Trypsin-EDTA was added. After removing Trypsin, HEK293T cells 
were collected with 3 ml DMEM from the plate and transferred into a falcon tube containing 7 ml 
medium. U2OS and PC3 cells were collected in trypsin, transferred into a falcon tube containing 5 ml 
Ham’s F-12 and RPMI, centrifuged (1’000 rpm, 3 min) and cell pellet was dissolved in fresh medium. 
Cells were then seeded directly or first counted with Casey Counter. 
 
4.2.2 Freezing and thawing of cultured cells 
To make cell aliquots, cells were trypsinized as previously described and centrifuged (1’000 rpm, 
3 min). Cells were resuspendend in 500 µl medium per aliquot. 500 µl cell suspension were pipetted 
into a 1 ml cryotube and 500 µl mix consisting of 200 µl medium, 200 µl FBS and 100 µl DMSO were 
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slowly added to the cells. The tube was inverted instantly, put into a box that was wrapped with 
paper towel to guarantee a slow freezing process and stored at -80 °C for 15-72 h before transferring it 
into liquid nitrogen. 
Cell aliquots were taken into culture by thawing them at 37 °C for 5-10 min. Cells were collected into 
a falcon tube and the cryotube was rinsed with 2 ml medium to collect all cells. After centrifugation 
(1’000 rpm, 5 min), cells were resuspended in fresh medium and seeded on a plate. 
 
4.2.3 Transient transfection 
4.2.3.1 Calcium phosphate transfection 
24 h prior transfection, cells were seeded. DNA mix was prepared as follows: 
 
Size of plate Cell number DNA 2.5 M CaCl2  H2O 
24-well plate 50’000 525 ng 732.5 nl  Fill up to 14.65 µl 
10 cm Ø plate 106 20 µg 50 µl  Fill up to 500 µl 
15 cm Ø plate 2.5 x 106 40 µg 100 µl  Fill up to 1 ml 
 
While vortexing the DNA mix, one volume of 2x BES solution was added dropwise. The mix was 
incubated for 10 s at room temperature and vortexed for another 10 s before distributing it equally on 
adherent cells. 
After 12 h, medium was changed and two or three days past transfection cells were harvested for 
analysis. 
 
4.2.3.2 X-tremeGENE HP transfection 
The X-tremeGene HP DNA Transfection Reagent was used to transfect PC3 cells for CoIP.  
5 x 106 cells were seeded on a 15 cm diameter plate and 24 h later cells were transfected. Transfection 
mix consisted of 20 µg DNA, 20 µl transfection reagent and 1960 µl Opti-MEM medium and was 
incubated 15 min at room temperature prior to the transfection. 
After 12h, mediudm was changed and three days past transfection cells were harvested for analysis. 
 
4.2.3.3 Lipofectamine® RNAiMAX transfection  
For each 6-well plate, 500 µl Opti-MEM were mixed with 4 µl siRNA in a 1,5 ml tube. After short 
vortexing, 4 µl Lipofectamine RNaiMAX were added and again vortexed. The mix was incubated for 
20 min at room temperature. 
PC3 cells were splitted, counted and diluted with medium to a concentration of 0.2 x 106 per ml. For 
each 6-well plate, 1 ml of cell suspension and the transfection mix were added and gently mixed by 
pipetting. U2OS cells were seeded in the same amount of medium with the same concentration as 
PC3 cells but 24 h before the transfection mix was added. 
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For ChIP 10 cm plates were transfected: 106 cells were seeded in 6 ml medium and the mix consisted 
of 24 µl siRNA, 24 µl Lipofectamine RNaiMAX and 3 ml Opti-MEM. 
Approximately 16 hours post transfection, medium containing transfection agents was removed and 
replaced by 2.5 ml standard medium. Three days past transfection, cells were collected for analysis. 
 
4.2.4 Retrovirus production 
Viruses were produced in HEK293T cells. 3 x 106 cells were seeded on a 10 cm diameter plate and 24 h 
later, cells were transfected with 6 µg pcDN-LBH, 6 µg LTR-G and 12 µg of the required plasmid. 
After 12 h, medium was replaced with standard medium. 24 h and 48 h later, medium containing 
virus particles was collected. Virus aliquots were centrifuged (3’000 rpm, 5 min), 9 ml of supernatant 
were taken carefully without contacting cell pellet, collected into a new falcon tube and stored at  
-80 °C. Tubes were labeled as day1 and day2. 
 
4.2.5 Retroviral transduction 
To transduce PC3 cells, 106 cells were seeded on a 10 cm diameter plate. 24 h later, virus aliquots from 
day1 and day2 were mixed together and 36 µg polybrene (PB) were added to 9 ml virus mix. 9 ml 
medium were removed from PC3 cells and virus-PB mix was added to the cells. 12 h later, the whole 
medium was replaced and three days after the infection cells were harvested for analysis or splitted.  
 
4.3 RNA analysis 
4.3.1 RNA extraction with TRIzol Reagent 
To isolate RNA, cells were lysed with 500 µl TRIzol Reagent and incubated for 5 min at room 
temperature. After centrifugation (10’000 rpm, 10 min, 4 °C), supernatant was transferred into a new 
1.5 ml safe lock reaction tube, 100 µl chloroform were added and after vigorous mixing, incubated for 
15 min at room temperature and centrifuged (12’000 rpm, 15 min, 4 °C). The aqueous phase 
containing RNA was transferred into a 1.5 ml safe lock reaction tube containing 250 µl isopropanol.  
1 µl glycogen was added to samples containing low RNA amounts. Samples were vortexed, RNA was 
pelleted by centrifugation (13’000 rpm, 10 min, 4 °C) and washed with 250 µl 75% EtOH (13’000 rpm, 
5 min, 4 °C). Prior to centrifugation, samples containing low amounts of RNA were incubated for  
10 min at -80 °C. Supernatant was discarded and RNA was air-dried. Pellets were dissolved in 40 µl 
H2O and incubated for 5 min in the heatblock at 60 °C. RNA concentration was measured with 
NanoDrop and RNA was stored at -80 °C. 
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4.3.2 RNA extraction with NucleoSpin RNA II Kit 
To isolate RNA, cells were washed with cold PBS and centrifuged (3’000 rpm, 5 min, 4 °C). All the 
following steps were performed at room temperature. Cell pellets were resuspended in 350 µl RA1 
buffer containing 3,5 µl β-mercaptoethanol and vortexed vigorously. The lysate was loaded into the 
violet column and centrifuged (11’000 g, 1 min). The column was discarded and 350 µl 75% EtOH 
were added to the flow through and mixed by pipetting. The mixture was transferred into the blue 
column and centrifuged (11’000 g, 30 s). Flow through was discarded and 350 µl MDB buffer were 
added to the blue column in order to dry the membran. After centrifugation (11’000 g, 1 min), the 
flow through was discarded and 95 µl DNAse mix (10 µl rDNAse and 90 µl 10x reaction buffer) were 
pipetted on the column membrane and incubated for 15 min at room temperature. 200 µl RA2 buffer 
were added, column was centrifuged (11’000 g, 30 s) and flow through discarded. 600 µl RA3 buffer 
were added, column was centrifuged (11’000 g, 30 s) and flow through discarded. Next, 250 µl RA3 
buffer were added and centrifuged (11’000 g, 2 min) to dry membrane. To elute RNA, the column was 
placed into a new safe lock reaction tube, 60 µl H2O were added on the column and centrifuged 
(11’000 g, 1 min). RNA concentration was measured with NanoDrop and samples were stored at  
-80 °C. 
 
4.3.3 Reverse transcription 
Reverse transcription reactions were performed in a total volume of 20 µl and contained 5.5 mM 
MgCl2, 1x RT buffer, 0.5 mM dNTPs, 0.5 µg dN6 random primers, 25 U MuLV Reverse Transcriptase, 
5 U RNase Inhibitor, 500-1’000 ng RNA and H2O. Reactions were incubated for 10 min at room 
temperature to allow hybridization of primers with RNA and then for 61 min at 42 °C followed by 
5 min at 90 °C. Synthesized cDNA was stored at -20 °C. Samples were diluted 1:5 prior to qPCR 
measurements. 
 
4.4 Quantitative PCR (qPCR) 
Quantitative PCR reactions were performed in 10 µl volume and contained 2 µl DNA or cDNA 
sample, 1x SYBR GREEN master mix, 2 pmoles forward primer, 2 pmoles reverse primer. To amplify 
CG rich regions (e.g. human rDNA sequences), reactions were performed in the presence of 3.25 M 
DMSO and 4 pmoles of each primer. Standard reaction conditions were as follows: 10 min at 95 °C; 
40-45 cycles of 20 s at 95 °C, 30 s at 55 °C or 60 °C and 30 s at 72 °C; melting from 55 °C or 60 °C to  
99 °C with steps of +1 °C, the first raise took 45 s and the following ones 10 s each. 
Quantifications were performed either using standard curve or Ct values. Standard curves represent 
serial dilutions of genomic DNA (100 ng to 0.1 ng) or cDNA (dilution 2:1, 1:1, 1:2 to 1:4). 
Quantifications by Ct were performed using the formula 2-ΔCt. ΔCt represents either CtSample – 
CtNormalization sample for cDNA samples or CtSample – CtInput for ChIP samples. 
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4.5 Protein analysis 
4.5.1 Chromatin extraction 
Cells were washed twice with 800 µl cold PBS (3’000 rpm, 5 min, 4 °C), resuspended with Chromatin 
Extraction buffer supplemented with 1x protease inhibitor (PI) and mixed by rotating on a wheel 
during 30 min at room temperature. Soluble and chromatin-bound proteins were separated by 
centrifugation (10’000 rpm, 10 min, 4 °C), supernatant was transferred into a new reaction tube and 
the pellet was resuspended in the same volume of Chromatin Extraction buffer + PI as used before. 
Protein concentration of soluble proteins was measured by Bradford assay using Chromatin 
Extraction buffer as blank. Supernatant was sonicated 1x 30s and resuspended pellet was sonicated 
several times till a low viscosity was reached.  
 
4.5.2 Co-Immunoprecipitation (CoIP) 
5 x 106 cells were seeded on a 15 cm diameter plate, transfected with HA-Flag- and control-plasmids 
and grown for 3 – 4 days.  
After removing medium, cells were harvested in 1.6 ml cold PBS, transferred into a 2 ml tube, 
centrifuged (3’000 rpm, 5 min, 4 °C) and washed twice with 800 µl cold PBS (3’000 rpm, 5 min, 4 °C). 
Pellets were then resuspended in 500 µl hypotonic buffer, centrifuged (8’000 rpm, 10 min, 4 °C) and 
nuclei were resuspended in 300 µl NE buffer. After sonication (twice for 30 s at 4 °C), 10 µl DNase I 
were added to the nuclear extracts and incubated for 1 h on ice (interrupted by short mixing every  
15 min). Then the samples were sonicated again 2x 30 s, centrifuged (6’000 rpm, 10 min, 4 °C) and 
supernatants were taken to perform Bradford protein assay. 
Anti-FLAG M2 beads were washed three times with 1 ml cold PBS (500 g, 5 min, 4 °C), two times 
with 1 ml NE buffer (500 g, 5 min, 4 °C) and then resuspended in NE buffer.  
For the input, 100 µg protein sample was stored at -20 °C. For the immunoprecipitation 1 mg protein 
sample was used and and diluted to 1 mg/ml using NE buffer (total volume 1 ml). Beads were 
equally distributed to samples and incubated at 4 °C overnight by gently rotation using a rotating 
wheel. 
IP samples were washed three times with 950 µl washing buffer. The washing steps consist of 
centrifugation (500 g, 5 min, 4 °C) and incubation with washing buffer (rotating on a wheel, 5 min,  
4 °C). Afterwards beads were resuspended in 40 µl 1x Laemmli buffer, boiled for 5 min at 95 °C, 
centrifuged and supernatant and the input samples (3x Laemmli buffer added, cooked 5 min at 95 °C) 
were analyzed by SDS-PAGE followed by western blot. 
 
4.5.3 Bradford protein assay 
To measure protein concentration the Bradford assay was performed. 5x Bradford buffer was diluted 
with H2O to 1x and 1 µl protein sample or adequate buffer were added.  
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Absorbance was measured at 595 nm using a spectrophotometer. The following formula was used to 
calculate the concentration: OD595 − 0.0950.065 = concentration µμg/µμl 
 
4.5.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins. Gels were made as follows: 
 
Solution components 6% Separation gel 15% Separation gel 5% Stacking gel 
H2O 5.8 ml 3.55 ml 3.6 ml 
40% acrylamide mix 1.5 ml 3.75 ml 0.63 ml 
1.5 M Tris (pH 8.8) 2.5 ml 2.5 ml  
1 M Tris (pH 6.8)   0.63 ml 
10% SDS 0.1 ml 0.1 ml 0.05 ml 
10% ammonium persulfate 0.1 ml 0.1 ml 0.05 ml 
TEMED 0.016 ml 0.008 ml 0.01 ml 
 
Polymerized gel was placed in a running unit that was filled with 1x Running buffer. Protein samples 
were supplemented with Laemmli buffer containing 10% β-mercaptoethanol and boiled at 95 °C for 
5 min before loading. Electrophoretic separation was performed at 120 V during 1-2 h. 
 
4.5.4.1 Coomassie staining 
Coomassie staining was performed to normalize protein amounts on a 15% histone gel. The gel was 
incubated 10 min in Coomassie blue solution (0.25% Coomassie blue, 40% methanol, 10% acetic acid) 
and afterwards destained with fast destainer solution (25% Ethanol, 10% acetic acid). 
 
4.5.5 Western blot 
Proteins separated by SDS-PAGE were blotted on a polyvinylidene fluoride (PVDF) membrane by 
wet transfer (see 4.5.5.1). Efficiency of protein transfer was checked by Ponceau staining (see 4.5.5.2). 
The membrane was blocked by incubation with blocking solution for 1 h and incubated with the 
primary antibody diluted in blocking solution with moderate shaking at 4 °C overnight or 3-5 h at 
room temperature. The membrane was washed twice 20 min with PBS-T and incubated with the 
secondary antibody for 1-3 h at room temperature by moderate shaking. After 2x 20 min wash steps 
in PBS-T, signals were detected by scanning two infrared channels with Odyssey. 
 
4.5.5.1 Wet transfer 
To perform wet transfer, a “sandwich” was assembled in a running unit filled with 1x transfer buffer 
as follows: a sponge, three blotting papers, a methanol-activated PVDF membrane, the 
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polyacrylamide gel, three blotting papers and on top a sponge. A cooling element and a magnetic 
stirrer were added to the unit, which was installed in the cold room (4 °C), run at 30 V overnight and 
at 100 V for the last hour.  
 
4.5.5.2 Ponceau staining 
To check transfer efficiency, membranes were incubated with Ponceau red (1% Ponceau S, 0.1% 
Acetic acid) for 2 min and destained with double distilled H2O. 
 
4.6 Chromatin immunoprecipitation (ChIP) 
106 or 2.5x 106 cells were seeded on a 10 or 15 cm diameter plate and grown for 4 days. 
Chromatin was crosslinked by adding 1% formaldehyde to the medium and incubating cells for 
10 min at room temperature. To stop crosslinking-reaction, 0.1 M glycine (final concentration) was 
included and the reaction was incubated for 10 min at room temperature. After removal of the 
medium, cells were collected, washed twice with 800 µl cold PBS (6’000 rpm, 5 min, 4 °C) and 
resuspended thoroughly in 600 µl buffer A to purify nuclei. Cells were incubated for 15 min at 4 °C, 
vortexed and then incubated for 15 min at 30 °C under light agitation. After centrifugation (6’000 rpm, 
5 min, 4 °C), supernatant was discarded and nuclei were resuspended in 500 µl buffer B and kept on 
ice for 5 min. After centrifugation (6’000 rpm, 5 min, 4 °C), nuclei were resuspended in 800 µl buffer C 
and incubated on ice for 5 min. After centrifugation (6’000 rpm, 5 min, 4 °C), nuclei were resuspended 
in 300 µl freshly prepared buffer D at room temperature.  
Chromatin was fragmented by ultra sonication using a sonifier. Samples were sonicated twice for 
15 min with cycles of 30 s on and 30 s off. Fragmented chromatin was centrifuged (7’000 rpm, 7 min) 
and supernatant transferred into a new reaction tube. 
To measure the concentration and check the size of sonicated chromatin, an aliquot of 5 µl chromatin 
was further analysed, while the rest of chromatin was stored at -80 °C. 5 µl chromatin were incubated 
with 20 µl Proteinase K mix (20 µg of Proteinase K in 0.39 M Tris-HCl (pH 8), 1.95 M NaCl and 0.1 M 
EDTA) in the presence of 300 µl elution buffer. The reaction was incubated for 1 h at 42 °C and 
overnight at 65 °C. After conclusion of the reaction, 350 µl phenol chloroform were added. Mixture 
was vortexed, centrifuged (7’000 rpm, 10 min), inverted and centrifuged again. The aqueous phase 
containing RNA and DNA was transferred into a new reaction tube containing 1 µl glycogen, 35 µl 
3M NaAcetate (pH5.5) and 700 µl absolute EtOH, vortexed, incubated 10 min at -80 °C and 
centrifuged (13’000 rpm, 10 min, 4 °C). The pellet was air-dried and dissolved in 20 µl H2O. The 
concentration of RNA and DNA was measured with NanoDrop. The size of the fragmented 
chromatin was analysed by incubating the samples with 0.2 µg RNase A for 20 min at 37 °C and 
analysing 1 µg of sample by agarose gel electrophoresis (1% agarose, 1x TAE, 120 V, 15 min). Only 
samples with a DNA size of 200-400 bp were used for ChIP assay. 
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To perform ChIP experiments, 5 µg of chromatin were used as input and stored at -20 °C. For each 
ChIP assay, 20 µg of chromatin were incubated with indicated antibodies in a reaction volume of 
500 µl containing 1x PI and ChIP buffer and mixed on a rotating wheel overnight at 4 °C. Agarose or 
magnetic beads were added and incubated on a wheel for 4 h at 4 °C. Bead-bound chromatin samples 
were washed (5 min incubation on a wheel; 6’000 rpm 1 min or 1 min on magnetic rack) as follows: 
2x 800 µl wash buffer 1, 1x 800 µl wash buffer 2, 2x 800 µl LiCl wash buffer, 1x 800 µl TE buffer and 
1x 500 µl TE buffer. Elution of chromatin from beads was performed by incubating the samples with 
300 µl elution buffer by rotation on a wheel for 20 min. Samples were centrifuged (6’000 rpm, 2 min) 
and supernatant was transferred into a new reaction tube containing 20 µl Proteinase K mix. Input 
samples were dissolved in 300 µl elution buffer and 20 µl of Proteinase K mix. Samples and inputs 
were incubated for 1 h at 42 °C and at 65 °C overnight. Phenol chloroform extraction and EtOH 
precipitation were performed as previously described. Pellets were air-dried and dissolved in 30 µl 
H2O for ChIP samples or 100 µl H2O for inputs. Target gene regions were analysed by qPCR. 
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5 Results 
5.1 TIP5 levels are upregulated in metastatic prostate cancer 
The study of Gazin et al. suggests that TIP5 and the histone methyltransferase enhancer of zeste 
homolog 2 (EZH2) might share a common pathway to epigenetically silence genes that are critical for 
cancer initiation and tumor development [97]. Previous studies showed that EZH2 is overexpressed 
in hormone-refractory, metastatic prostate cancer [65] and that strong EZH2 expression is associated 
with increased tumor cell proliferation in different cancer types as well as with decreased long time 
survival rate in metastatic prostate cancer [63]. Interestingly, previous results from our laboratory 
identified EZH2 as TIP5-interacting protein in HEK293T cells. 
As already shown in my master thesis, we analyzed gene expression profiles (GDS1439 and GDS2545) 
published at Gene Expression Omnibus database (GEO) for TIP5 and EZH2 expression levels in 
different prostate tissues including normal prostate tissue, tissue adjacent to tumor, clinically 
localized and metastatic tumors (Figure 4). As expected, EZH2 expression levels were higher in 
metastatic tumor tissue compared to benign and clinically localized samples. Notably, also TIP5 
levels increased in the metastatic samples while the expression of the Pol I transcription factor UBF 
was not affected. These results suggest that TIP5 and EZH2 might share a common pathway to 
epigenetically silence genes in metastatic cancer. 
 
 
Figure 4 | Increased TIP5 expression levels in metastatic prostate tumors
A | GEO expression profiling (GDS1439) of 6 benign prostate tissue samples (4 samples and 2 pooled samples),
7 clinically localized primary prostate cancer tissue samples (5 samples and 2 pooled samples) and 6 hormone-­‐
refractory metastatic prostate cancer tissue samples (4 samples and 2 pooled samples). B | GEO expression
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profiling (GDS2545) of normal prostate tissues from 18 donors, normal prostate tissue adjacent to the tumor
of 63 donors, 65 primary prostate tumor samples and 25 metastatic prostate tumor samples (location of
metastatic samples: 5 liver, 1 lung, 1 recurrent in prostate, 1 kidney, 2 adrenal gland, 3 retroperitoneal lymph
node, 1 inguinal lymph node, 8 para-­‐tracheal lymph node, 3 para-­‐aortic lymph node). Expression profiles of
TIP5, EZH2 and UBF are shown.
 
5.2 TIP5 and EZH2 regulate genes implicated in developmental processes in metastatic prostate 
cancer cells (PC3) 
Based on the results described above, we carried out a transcriptomic analysis to determine whether 
TIP5 regulates together with EZH2 gene expression in metastatic prostate cancer cells. We performed 
a RNA exon microarray analysis to measure and compare transcript levels of metastatic prostate 
cancer cells PC3 that were depleted either of TIP5 or EZH2 by siRNA. As control we used PC3 cells 
transfected with siRNA-CTRL (control).  
Transcriptomic analysis revealed that TIP5 regulates 1904 genes and EZH2 1787 genes in PC3 cells 
(fold change > 1.5 or < 0.75 and P < 0.005; Figure 5). Remarkably, 626 genes are regulated by both 
TIP5 and EZH2, indicating that about 30% of genes regulated by TIP5 are also regulated by EZH2 and 
vice versa (Figure 5). We classified genes both regulated by EZH2 and TIP5 into two groups: 
upregulated and downregulated transcription upon knockdown of TIP5 or EZH2. Of the 626 genes 
that were regulated by both TIP5 and EZH2, 309 genes (49%) were both upregulated by depletion of 
TIP5 or EZH2 and 276 (44%) both downregulated, indicating that TIP5 and EZH2 affect transcription 
levels in a similar manner and might probably operate on the same pathway. 
We named the 309 genes whose expression increased upon knockdown of both TIP5 and EZH2 
RTEM (repressed by TIP5 and EZH2 in metastasis) genes. The counterpart of 276 downregulated 
genes we referred to as ATEM (activated by TIP5 and EZH2 in metastasis) genes. 
 
In order to determine which biological functions characterize those genes regulated by TIP5 and/or 
EZH2 in PC3 cells we performed Gene Ontology (GO) term biological functional analysis with the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) according to the protocol 
published in Nature Protocols 4, 2009 [102]. The top seven functional categories of every gene 
subgroup are shown in Figure 5. Remarkably, upregulated genes in PC3 cells depleted of TIP5 or 
EZH2 were highly enriched in developmental processes whereas the downregulated genes are 
related to immunological processes and responses to different stimuli. RTEM and ATEM genes 
displayed similar functional classifications, indicating that TIP5 and EZH2 operate on the same 
biological processes in metastatic prostate cancer cells. Of note is the enrichment of genes upregulated 
by TIP5 or EZH2 in developmental processes. Indeed, EZH2 is well known to be a key regulator of 
embryonic stem cell self-renewal and accumulating evidences suggested prostate cancer stem cells to 
be responsible for tumor initiation, progression, therapy resistance, relapse and metastasis [63, 103]. 
Sandra Frommel, PhD student of Dr. Santoro’s laboratory, performed a similar transcriptomic 
analysis with non-cancer epithelial prostate cells RWPE1. Interestingly, genes regulated by TIP5 and 
EZH2 in RWPE1 cells were enriched in cell cycle processes but not in developmental processes (data 
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not shown). These results strongly suggested that the function of TIP5 and EZH2 in neoplastic cells is 
not the same one as in normal cells. 
 
Figure 5 | Analysis of exon microarray data upon siRNA-­‐mediated TIP5 and EZH2 knockdown in PC3 cells
PC3 cells were transfected with siRNA-­‐CTRL, -­‐TIP5 and EZH2 and three days post-­‐transfection RNA was isolated
with NucleoSpin RNA II Kit and passed to the Functional Genomics Center of the University of Zurich. The exon
microarray was performed with three biological replicates.
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In the upper part of the figure, the numbers of genes are shown that have a different expression upon TIP5 or
EZH2 knockdown compared to siRNA-­‐CTRL transfected cells. 1904 genes showed an altered expression upon
TIP5 knockdown, 1787 upon EZH2 knockdown and 626 genes’ expression was changed by TIP5 and EZH2
knockdown. These genes were further divided into two groups: upregulated or downregulated expression.
41 genes of the 626 that were influenced by TIP5 and EZH2 knockdown could not be subdivided, as they do
not react in the same way on both knockdowns.
The six lower panels show Gene Ontology (GO) analysis of upregulated and downregulated genes. Analysis was
performed with the Database for Annotation, Visualization and Integrated Discovery 6.7 (DAVID 6.7,
http://david.abcc.ncifcrf.gov/). P values of the top seven functional categories are shown.
 
5.3 Genes repressed by TIP5 and EZH2 in metastasis (RTEM genes) 
To select genes that are directly regulated by TIP5 and EZH2 in PC3 cells and functionally relevant to 
cancer, we used the following criteria: 
 
1. Genes upregulated in PC3 cells upon siRNA-TIP5 and siRNA-EZH2 treatment 
Since TIP5 and EZH2 are transcriptional repressors, we reasoned to select genes that showed 
transcriptional upregulation upon knockdown of TIP5 and EZH2 in PC3 cells in our 
microarray analysis. 
2. Genes transcriptionally repressed in cancer and metastatic prostate cancer 
We initially analyzed expression profiles (GDS1439 and GDS2545) of RTEM genes and 
selected genes that were transcriptionally repressed in metastatic prostate tissues (Figure 6 A 
and B). We also investigated the current literature and selected those RTEM genes that were 
previously described to be transcriptionally repressed and implicated in cancer progression. 
 
Using these criteria, we selected 10 RTEM genes that will be used for subsequent analyses. 
These genes are listed in Table 1. 
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Table 1 | List of RTEM genes that were selected for further analyses
RTEM gene Full name Function 
AOX1 Aldehyde oxidase 1 Production of hydrogen peroxide 
 
FBN1 Fibrillin 1 Extracellular matrix glycoprotein 
 
FHL2 Four and a half LIM domains 2 Assembly of extracellular membranes, 
transcriptional coregulator 
HOMER2 Homer homolog 2 (Drosophila) Regulator of glutamate receptor function, 
scaffolding protein 
HOXA7 Homeobox A7 Transcription factor, involved in 
morphogenesis and differentiation 
HOXB8 Homeobox B8 Transcription factor, involved in 
developmental regulation 
KLF6 Krüppel-like factor 6 Zinc finger protein, transcriptional 
activator 
LAMB3 Laminin, beta 3 Attachment, migration and organization of 
cells into tissues 
MKX Mohawk homeobox Transcription factor, regulator of cell 
adhesion 
ZNF185 Zinc finger protein 185 (LIM domain) Regulation of cellular 
proliferation/differentiation 
 
Aldehyde oxidase 1 (AOX1) is a variant of aldehyde oxidase (AO), a complex molybdoflavoprotein 
that belongs to the xanthine oxidase family. An early study showed that AOX1 activity could be 
measured in normal liver but not in tumor [104]. Another study showed reduced AOX1 expression in 
hepatocellular carcinomas and that the loss of AOX1 was associated with higher tumor stages, 
positive nodal status and occurrence of distant metastases [105]. Normal pancreatic acinar cells 
showed a strong expression of AOX1 but a complete loss of AOX1 in pancreatic ductal 
adenocarcinoma [106]. Additionally, AOX1 was found hypermethylated in colorectal cancer [107, 108] 
and in prostate cancer [109, 110] where the hypermethylation was associated with reduced AOX1 
gene expression [111]. 
 
The gene Fibrillin 1 (FBN1) encodes a member of the fibrillin family. The encoded protein is a large, 
extracellular matrix glycoprotein that serves as a structural component of 10-12 nm calcium-binding 
microfibrils. These microfibrils provide force bearing structural support in elastic and non-elastic 
connective tissue throughout the body [112]. Recently, increased expression of FBN1 was associated 
with low proliferation in non-small cell lung cancer [113]. FBN1 was identified as cancer-related gene 
in primary breast cancer [114]. In colorectal adenomas and cancers, FBN1 was frequently 
hypermethylated and the DNA methylation was associated with reduced or lost gene expression in 
cell lines [115]. FBN1 was also found hypermethylated in prostate cancer cells (PC3M) compared to 
immortalized prostate epithelial cells (267B1) associated with a reduced RNA expression [116, 117]. 
 
Four and a half LIM domains 2 (FHL2) gene encodes a member of the four-and-a-half-LIM-only 
protein family. Family members contain two highly conserved, tandemly arranged zinc finger 
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domains with four highly conserved cysteines binding a zinc atom in each zinc finger. This protein is 
thought to have a role in the assembly of extracellular membranes [112]. FHL2 was suggested to act 
as an oncoprotein or a tumor suppressor in a tissue-dependent manner [118]. FHL2 was found 
overexpressed in several human osteosarcoma cell lines and correlated positively with aggressiveness, 
indicating a positive role of FHL2 in bone tumor development [119]. Overexpression of FHL2 was 
also found in breast cancer tissue samples [120], in glioma tissue samples [121], in bone marrow 
samples of acute erythroid leukemia patients [122], in epithelial ovarian cancer [123], in colon 
adenomas and carcinomas [124] as well as in cancerous gastric and colon tissue samples [125]. On the 
other hand, FHL2 showed tumor suppressor function in colon carcinoma cell line HT-29 that exhibits 
very low basal levels of FHL2 [126] and 7 of 8 breast cancer cell lines expressed FHL2 mRNA much 
lower than an immortalized normal breast epithelial cell line [127]. Downregulated FHL2 expression 
was detected in liver cancer patient samples [128], in rhabdomyosarcoma cell lines [129] and in early 
prostate cancer samples [130]. In LNCaP prostate adenocarcinoma cells androgen exposure led to an 
increase in FHL expression at mRNA and protein levels [131]. 
 
Homer homolog 2 (HOMER2) gene encodes a member of the homer family of dendritic proteins [112]. 
Members of this family regulate group 1 metabotrophic glutamate receptor function. HOMER2 was 
found to be hypermethylated in primary colorectal cancers [132]. The expression of HOMER2 was 
shown to enhance the ability of MYO18B to suppress anchorage-independent growth in human non-
small cell lung carcinoma cell line H1299, suggesting that HOMER2 may have a tumor suppressor 
role [133]. 
 
In vertebrates, the genes encoding the class of transcription factors called homeobox genes are found 
in clusters named A, B, C and D on four separate chromosomes. Expression of these proteins is 
spatially and temporally regulated during embryonic development. Homeobox A7 (HOXA7) gene is 
part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may 
regulate genes expression, morphogenesis and differentiation [112]. HOXA7 was found to be 
overexpressed in 16 glioma samples compared to primary astrocytes [134] and in esophageal 
squamous cell carcinoma tissue samples compared to noncancerous mucosa, too [135]. Novak et al., 
2006 showed a decrease in the expression of HOXA7 in breast cancer samples when compared to 
normal breast tissue and confirmed it in cell line models as well. The authors concluded that the 
silencing of the HOXA gene cluster in breast cancer is associated with the acquisition of the repressive 
epigenetic mark of DNA hypermethylation and the loss of permissive histone modifications [136]. 
Further HOXA7 was studied in several other cancers such as leukemia [137-140], ovarian tumors 
[141-144], lung cancer [145, 146], hepatocellular carcinomas [147] and oral squamous cell carcinomas 
[148]. 
 
Homeobox B8 (HOXB8) gene is a member of the Antp homeobox family and encodes a nuclear 
protein with a homeobox DNA-binding domain. It is included in a cluster of homeobox B genes 
located on chromosome 17. The encoded protein functions as a sequence-specific transcription factor 
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that is involved in development [112]. HOXB8 was reported to be overexpressed in colorectal cancer 
whereas the level in the tested esophageal and gastric cancers was below detection [149]. In HT-29 
cells (human colorectal adenocarcinoma) and in CACO-2 cells (human Caucasian colon 
adenocarcinoma) HOXB8 was found to be upregulated as well, but in LS174T cells (Dukes type B, 
colorectal adenocarcinoma) it was downregulated [150]. In colorectal cancer HOXB8 was negatively 
correlated with chemotherapy [151]. HOXB8 was found to be overexpressed in serous ovarian cancer 
[152] and its expression was associated with poorer outcome [153]. HoxB8 was the first Hox protein 
found to be transcriptionally activated in murine acute myeloid leukemia (in WEHI3B mouse 
myeloid leukemia cells) and its overexpression was shown to prevent differentiation of myeloid 
progenitors [154]. Moreover, several studies analyzed HoxB8 in terms of inhibited myeloid 
differentiation [155-158]. 
 
Krüppel-like factor 6 (KLF6) gene encodes a member of the Krüppel-like family of transcription 
factors [112]. Different studies described KLF6 as a novel tumor suppressor gene involved in growth 
suppression and differentiation stimulation [159-165]. KLF6 was found mutated or downregulated in 
astrocytic gliomas [166], in colorectal cancer [167, 168], in lung cancer [165, 169, 170], in esophageal 
cancer [171, 172], in hepatocellular carcinoma [173, 174], in gastric cancer [175], in epithelial ovarian 
cancer [176] and in prostate cancer [163, 177]. In prostatic carcinoma DU145 and renal carcinoma  
OS-RC-2 cell lines overexpression of KLF6 was shown to inhibit proliferation and to enhance the 
amounts of cells with apoptotic signals [178]. 
 
The product encoded by Laminin, beta 3 (LAMB3) gene is a laminin that belongs to a family of 
basement membrane proteins. This protein is a beta subunit laminin, which forms laminin-5 together 
with an alpha and a gamma subunit [112]. LAMB3 was reported to be upregulated in nasopharyngeal 
carcinoma [179], in biliary cancer [180] and in esophageal squamous cell carcinoma [181]. On the 
other hand it was downregulated in lung cancer [182] and in bladder cancer [183] and methylated in 
small bowel carcinoid tumors [184]. In six prostate cancer cell lines LAMB3 expression was shown to 
be decreased and the methylation frequency was increased; the hypermethylation was confirmed in 
prostate cancer tissues [185]. Restoration of LAMB3 beta 3A isoform expression in LNCaP cells led to 
increased cell spreading and migration in vitro and when injected into mice to increased tumor 
growth [186]. Another study described the LAMB3 expression in different stages of prostate cancer: 
LAMB3 was maintained in localized and lymph node metastases but was almost completely absent in 
bone metastases [187]. 
 
The protein encoded by Mohawk homeobox (MKX) gene is an IRX family-related homeobox protein 
that may play a role in cell adhesion[112]. So far, there is no report concerning the role of MKX in 
cancer. However, we decided to include MKX in our analysis since homeobox genes have been 
demonstrated to play important roles during cancer differentiation and embryonic development. 
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Zinc finger protein 185 (ZNF185) gene encodes a LIM-domain zinc finger protein. The LIM domain is 
composed of two contiguous zinc finger domains, separated by a two-amino acid residue 
hydrophobic linker and mediates protein-protein interactions [112]. ZNF185 was shown to be 
overexpressed in leiomyoma samples compared to myometrium [188]. ZNF185 expression was 
decreased in lung primary tumors and lung cancer cell lines [189], in head and neck squamous cell 
carcinomas and cell lines [190] and in prostate cancer [191]. Treatment of LAPC4, LNCaP and PC3 
prostate cancer cell lines with 5-Aza-CdR showed an ∼2-fold increase in mRNA levels of ZNF185 
indicating that the gene might be partially silenced by methylation [191]. Overexpression of full-
length ZNF185 in LNCaP and DU145 cells was found associated with slower cell growth [192]. 
 
As shown in Figure 6, most of the RTEM genes (AOX1, FBN1, FHL2, HOXA7, LAMB3, MKX, ZNF185) 
showed a lower expression level in prostate cancer tissue than in normal prostate tissue and also a 
further reduction of the level in metastatic prostate cancer compared to localized prostate tumors. 
HOMER2 and KLF6 did not show such a transcriptional profile in the analyzed arrays. However, we 
decided to include these genes in our analysis due to strong evidences reported in literature (see 
above) describing down-regulation and tumor suppressor features in prostate and other types of 
cancer.  
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Figure 6 | Decreased RTEM genes expression levels in metastatic prostate tumors
A | GEO expression profiling (GDS1439) of 6 benign prostate tissue samples (4 samples and 2 pooled samples),
7 clinically localized primary prostate cancer tissue samples (5 samples and 2 pooled samples) and 6 hormone-­‐
refractory metastatic prostate cancer tissue samples (4 samples and 2 pooled samples). Expression profiles of
AOX1, FBN1, FHL2, HOMER2, HOXA7, KLF6, LAMB3, MKX and ZNF185 are shown.
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Figure 6 | Decreased RTEM genes expression levels in metastatic prostate tumors
B | GEO expression profiling (GDS2545) of normal prostate tissues from 18 donors, normal prostate tissue
adjacent to the tumor of 63 donors, 65 primary prostate tumor samples and 25 metastatic prostate tumor
samples (location of metastatic samples: 5 liver, 1 lung, 1 recurrent in prostate, 1 kidney, 2 adrenal gland, 3
retroperitoneal lymph node, 1 inguinal lymph node, 8 para-­‐tracheal lymph node, 3 para-­‐aortic lymph node).
Expression profiles of AOX1, FBN1, FHL2, HOMER2, KLF6, LAMB3 and ZNF185 are shown.
 
5.4 Analysis of RTEM genes’ expression levels in prostate and osteosarcoma cancer cell lines 
Since RTEM genes are upregulated after knockdown of TIP5 and EZH2, we reasoned that their 
expression levels must be lower in cancer cells when compared to non-cancer cells. To test this, we 
measured and compared RTEM transcription levels in 3 different cancer cell lines: human metastatic 
prostate adenocarcinoma cell line PC3, human androgen-sensitive metastatic prostate carcinoma cell 
line LNCaP and human osteosarcoma cell line U2OS. The choice of U2OS was motivated by the fact 
that this cell line is very well described for the EZH2-mediated silencing process (see 5.5) and TIP5 
was found upregulated in this cell line [99]. The analysis of human prostate epithelial cell line RWPE1 
- that are of non-cancer origin - represents a further control of this analysis. Measurements were 
AOX1 GDS2545
0
200
400
600
800
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
HOMER2 GDS2545
0
500
1000
1500
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
LAMB3 GDS2545
0
100
200
300
400
500
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
FBN1 GDS2545
0
200
400
600
800
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
FHL2 GDS2545
0
500
1000
1500
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
KLF6 GDS2545
0
200
400
600
800
1000
1000
1500
2000
2500
3000
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
ZNF185 GDS2545
0
100
200
300
400
500
Normal prostate tissue
Normal tissue adjactent to tumor
Prostate tumor
Metastatic prostate tumor
Ex
pr
es
si
on
 le
ve
ls
B
 43 
performed by RT-qPCR and transcript levels were normalized to 28S rRNA that serves to equalize the 
total amounts of RNA between samples. Indeed, classical housekeeping genes could not be used for 
normalization as their expression levels differ among the analyzed different cell lines. 
Compared to non-cancer prostate epithelium RWPE1 cells, TIP5 levels were higher in PC3 and U2OS 
cells while LNCaP cells did not display elevated TIP5 expression. Whether the expression levels of 
TIP5 might distinguish the androgen-sensitive signature of prostate cancer will be an issue of future 
studies. Remarkably, EZH2 was overexpressed in all three analyzed cancer cell lines (Figure 7 A). 
Interestingly, a recent study showed overexpression of EZH2 in osteosarcoma cell lines and patient 
samples [193]. The elevated levels of TIP5 and EZH2 measured in U2OS cells might suggest the 
existence of a crosstalk between TIP5 and EZH2 also in osteosarcoma cancer. 
 
Analysis of RTEM gene expression levels revealed that only FHL2, HOMER2, HOXA7 and LAMB3 
are higher expressed in RWPE1 cells than in PC3 cells (Figure 7 B). HOXB8 could not be included in 
this analysis due to the lack of primers able to efficiently amplify the selected transcript. All RTEM 
genes were strongly downregulated in LNCaP cells except HOMER2 and FBN1, indicating that 
expression levels of these two RTEM genes in LNCaP cells do not depend on TIP5 expression levels. 
For example, HOMER2 showed the highest expression level in LNCaP cells and is strongly 
downregulated in PC3 cells (Figure 7 B). Consistent with a previous study, KLF6 displayed the 
highest expression level in PC3 cells, followed by RWPE1 and nearly no expression in LNCaP cells 
[177], supporting the accuracy of our analysis. These results indicated that the lowest expression level 
of RTEM genes characterizes androgen-sensitive metastatic prostate cancer cell line LNCaP. 
Moreover, they indicated that although RTEM gene transcription is upregulated in PC3 cells upon 
TIP5 or EZH2 knockdown, RTEM expression levels in PC3 cells are not significantly downregulated 
when compared to non-cancer cells. As RTEM genes are transcriptionally silenced in metastatic 
prostate tissues (Figure 6), we conclude that the use of PC3 cells is instructive to determine which and 
how these genes are regulated by TIP5 and EZH2 but not to determine the correlation between 
transcriptional state and cancer progression. 
 
A previous report showed downregulation of KLF6 in osteosarcoma cell lines (MG63 and Saos2) 
when compared to normal bone control cells (hFOB1.19). Similarly, in osteosarcoma tissues KLF6 
levels were shown to be lower than in normal bone tissue [194]. Compared to RWPE1 cells, U2OS 
cells displayed equal to higher expression levels of RTEM genes (including KLF6) with the exception 
of FHL2 and LAMB3 that showed lower levels (Figure 7 B). A limitation of our analysis is that 
RWPE1 does not represent the correct cell line to be compared with U2OS cells. Thus, the lack of 
RTEM transcriptional analysis in a benign bone cell line does not allow a functional analysis for these 
results. 
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Figure 7 | RTEM genes show different expression levels in different cell types
RNA from RWPE1, PC3 and LNCaP cells was prepared and isolated by Sandra Frommel, PhD student of
Dr. Santoro’s laboratory.
A | RT-­‐qPCR. TIP5 and EZH2 mRNA levels measured in U2OS, RWPE, PC3 and LNCaP wildtype cells. mRNA
levels were normalized against 28S rRNA. B | RT-­‐qPCR. AOX1, FBN1, FHL2, HOMER2, HOXA7, KLF6, LAMB3,
MKX and ZNF185 mRNA levels measured in U2OS, RWPE, PC3 and LNCaP wildtype cells. mRNA levels were
normalized against 28S rRNA. 
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Figure 7 | EZH2-­‐target genes show different expression levels in different cell types
C | RT-­‐qPCR. ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 (two different primer pairs) mRNA levels measured in
U2OS, RWPE, PC3 and LNCaP wildtype cells. mRNA levels were normalized against 28S rRNA. 
 
5.5 Analysis of known EZH2-target genes’ expression levels in prostate and osteosarcoma cancer 
cell lines 
The role of EZH2 in cancer has been well analyzed in the recent years [63-65, 195, 196]. The oncogenic 
function of EZH2 was suggested to be mainly mediated through its gene silencing activity and 
several EZH2-target genes were identified [51]. ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 are well 
known EZH2-target genes that are implicated in cancer. With the aim to determine whether TIP5 is 
involved in the EZH2-mediated silencing process of these genes, we initially measured and compared 
their expression in RWPE1, PC3, LNCaP and U2Os cells. 
 
Adrenoceptor beta 2, surface (ADRB2) gene encodes a beta-2-adrenergic receptor that is a member of 
guanine-nucleotide-binding protein (G protein)-coupled receptor superfamily [112]. Polymorphisms 
of the ADRB2 gene were associated with an increased risk of breast and colorectal cancer [197] but 
not with lung cancer [198]. ADRB2 was identified as a direct target of EZH2 in prostate cancer and 
found downregulated in metastatic prostate cancer samples with a negative correlation to EZH2 
expression [199]. However, in our analysis both PC3 and LNCaP cells showed higher ADRB2 
expression when compared to RWPE1 and we could not establish a negative correlation with EZH2 
expression (Figure 7 A and C). Only in U2OS cells, ADRB2 showed low expression level (Figure 7 C). 
Consistent with a previous report showing that ADRB2 was significantly higher in androgen-
independent prostate cancer cell lines (LNCaP-C4, LNCaP-C4-2 and DU145) than in androgen-
sensitive LNCaP cells [200], we found that ADRB2 levels were higher in PC3 cells than in LNCaP, 
underscoring the accuracy of our analysis. 
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Disabled homolog 2 interacting protein (DAB2IP) is a GTPase-activation protein (GAP) that 
modulates the Ras-mediated signaling and tumor necrosis factor-mediated apoptosis. The expression 
of this tumor suppressor was reported to be epigenetically suppressed by EZH2 in prostate cancer 
[196, 201]. DAB2IP was downregulated in human prostate cancer samples [196], in pancreatic cancer 
tissue samples [202], in hepatcocellular carcinoma tissue samples and cells [203], in human 
medulloblastoma cells [204], in lung cancer cell lines [205], in gastrointestinal cancer cell lines [206] 
and in breast cancer cell lines [207] whereas the last three were associated with methylation status. 
Further, DAB2IP mRNA levels were found lower in six prostate cancer cell lines (MADPC2a, 
MADPC2b, Du145, LNCaP, TSU-Pr1 and PC3) compared to three normal prostate epithelia cell lines 
(PrEC, SWNPC2 and PZ-HPV-7) [208]. Consistent with these results, we found the levels of DAB2IP 
were strongly downregulated in PC3 and LNCaP cells when compared to RWPE1 (Figure 7 C). In 
contrast, U2OS displayed similar DAB2IP levels than RWPE1 cells. 
 
The gene cannabinoid receptor 1 (brain) (CNR1) encodes one of two cannabinoid receptors that are 
members of the G protein-coupled receptor family, which inhibit adenylate cyclase activity. The two 
receptors were found to be involved in the cannabinoid-induced CNS effects experienced by users of 
marijuana [112]. CNR1 was identified as a target gene of PRC2 complex of which EZH2 is a 
component [209]. Several studies reported anti-tumor effects of CNR1 signaling such as  
Δ9-tetrahydrocannabinol (THC) inhibited proliferation in several human breast cancer cell lines due 
to blockade of the G2-M transition [210] or the growth of melanoma cell but not normal melanocytes 
was inhibited by activation of cannabinoid receptors with cannabinoids [211]. In hepatocellular 
carcinoma, high expression of CNR1 was significantly associated with improved prognosis [212]. 
CNR1 expression was lower in human breast tumors than in noncancerous breast tissue [210] but 
upregulated in mantle cell lymphomas [213, 214]. As shown in Figure 7 C, CNR1 mRNA levels were 
significantly downregulated in prostate cancer cells PC3, LNCaP and osteosarcoma cells U2OS 
compared to prostate epithelial cells RWPE1. 
 
Potassium voltage-gated channel, shaker-related subfamily, member 1 (KCNA1) encodes a voltage-
gated delayed potassium channel that is phylogenetically related to the Drosophila Shaker channel. It 
mediates the voltage-dependent potassium ion permeability of excitable membranes [112]. KCNA1 
was shown to be a target gene of PRC2 and to be bound by EZH2, which is a component of the PRC2 
complex in U2OS and SW480 cells [209]. KCNA1 was less expressed in human cancerous breast than 
in normal breast tissue [215] and low levels of KCNA1 in breast cancer were associated with an 
increased risk of metastasis and of dying [216]. As shown in Figure 7 C, expression of KCNA1 was 
strongly downregulated in PC3 and LNCaP cells while U2OS cells displayed elevated expression 
levels. 
 
The protein encoded by myelin transcription factor 1 (MYT1) gene is a member of a family of neural 
specific, zinc finger-containing DNA-binding proteins that binds to the promoter regions of 
proteolipid proteins of the central nervous system [112]. MYT1 was shown to be a target gene of 
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PRC2 and of EZH2 in U2OS and SW480 cells [209]. Consistent with these results, MYT1 expression 
was significantly downregulated in PC3, LNCaP and U2OS cells (Figure 7 C). 
 
Taken together, the results of this analysis revealed that expression of known EZH2-target genes is 
also significantly downregulated in prostate cancer cells. Understanding whether EZH2 and/or TIP5 
are implicated in the transcriptional repression of these genes in U2OS (and PC3) cells is an aim of 
this study. 
 
5.6 TIP5 knockdown affects expression levels of RTEM genes in U2OS and PC3 cells 
To validate the results of the microarray, we measured and compared transcript levels of the selected 
RTEM genes by RT-qPCR in PC3 cells depleted of TIP5 or EZH2. All analyzed RTEM genes were 
higher expressed upon knockdown of TIP5 and EZH2 when compared to control cells (siRNA-CTRL, 
Figure 8 A and B). 
To determine whether the regulation of RTEM genes by TIP5 and EZH2 is cancer specific, we 
extended our analysis to U2OS and RWPE1 cells and measured transcription of RTEM genes upon 
TIP5 or EZH2 knockdown (Figure 8 A and B). Remarkably, transcription of RTEM genes was not 
affected in RWPE1 cells by depletion of TIP5 or EZH2 (except FHL2), indicating that TIP5 and EZH2 
regulation is specific to prostate cancer cells. Importantly, 6 out of the 9 analyzed RTEM genes were 
also upregulated in U2OS cells upon TIP5 or EZH2 depletion, suggesting that the role of TIP5 and 
EZH2 to regulate RTEM genes’ transcription is not limited to prostate cancer, but is also true in 
osteosarcoma cells. Future studies will address whether TIP5 is implicated in other cancer types. 
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Figure 8 | Expression analysis of RTEM genes upon siRNA-­‐mediated TIP5 and EZH2 knockdown in U2OS,
RWPE1 and PC3 cells
The experiments with RWPE1 and PC3 cells were performed by Sandra Frommel, PhD student of Dr. Santoro’s
laboratory. Error bars indicate SD of two (RWPE1) or three (U2OS and PC3) independent experiments.
A | RT-­‐qPCR. TIP5 and EZH2 mRNA levels in U2OS, RWPE1 and PC3 cells transfected with siRNA-­‐CTRL, -­‐TIP5
and -­‐EZH2. Values of TIP5 and EZH2 mRNA levels were first normalized to L28 or GAPDH mRNA levels and then
to levels of siRNA-­‐CTRL transfected cells. B | RT-­‐qPCR. AOX1, FBN1, FHL2, HOMER2, HOXA7, KLF6, LAMB3,
MKX and ZNF185 mRNA levels in U2OS, RWPE1 and PC3 cells transfected with siRNA-­‐CTRL, -­‐TIP5 and -­‐EZH2.
Values of RTEM genes mRNA levels were first normalized to L28 or GAPDH mRNA levels and then to levels of
siRNA-­‐CTRL transfected cells.
TIP5
U2
OS
RW
PE
1
PC
3
0.0
0.5
1.0
1.5
2.0
2.5
siRNA-CTRL
siRNA-TIP5
siRNA-EZH2
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
AOX1
U2
OS
RW
PE
1
PC
3
0
2
4
6
8
10
siRNA-CTRL
siRNA-TIP5
siRNA-EZH2
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
HOMER2
U2
OS
RW
PE
1
PC
3
0
1
2
3
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
LAMB3
U2
OS
RW
PE
1
PC
3
0
1
2
3
4
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
EZH2
U2
OS
RW
PE
1
PC
3
0.0
0.5
1.0
1.5
2.0
2.5
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
FBN1
U2
OS
RW
PE
1
PC
3
0
2
4
6
8
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
HOXA7
U2
OS
RW
PE
1
PC
3
0
1
2
3
4
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
MKX
U2
OS
RW
PE
1
PC
3
0
2
4
6
8
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
FHL2
U2
OS
RW
PE
1
PC
3
0
1
2
3
4
5
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
KLF6
U2
OS
RW
PE
1
PC
3
0
1
2
3
4
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
ZNF185
U2
OS
RW
PE
1
PC
3
0
1
2
3
4
5
Cell type
m
R
N
A 
ex
pr
es
si
on
(fo
ld
 c
ha
ng
e)
A
B
 49 
5.7 TIP5 knockdown affects 45S pre-rRNA levels in U2OS cells 
The results described so far indicated that TIP5 is implicated in the transcriptional regulation of 
RTEM genes. Due to the exclusive nucleolar localization of TIP5 in mouse cells, the first gene 
described to be regulated by TIP5 was the ribosomal RNA (rRNA) gene [81]. In NIH/3T3 and 
HEK293T cells the knockdown of TIP5 leads to a decrease in the number of silent rRNA genes and 
thereby to enhanced rRNA transcription [96]. To determine whether TIP5 maintains its role in 
repressing rRNA transcription in U2OS cells, we measured 45S pre-rRNA levels by RT-qPCR upon 
knockdown of TIP5 or EZH2. As shown in Figure 9 A, depletion of TIP5 caused a ~1.9 fold increase in 
rRNA synthesis when compared to control cells (siRNA-CTRL). Of note is that EZH2 knockdown did 
not significantly affect rRNA transcription, indicating that TIP5-mediated silencing of rRNA genes is 
independent of EZH2. We conclude that in U2OS cells TIP5-mediated regulation of rRNA genes is 
independent of EZH2. 
 
 
Figure 9 | Expression analysis of 45S pre-­‐rRNA, ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 upon siRNA-­‐mediated
TIP5 and EZH2 knockdown in U2OS cells
Error bars indicate SD of three independent experiments.
A | RT-­‐qPCR. 45S pre-­‐rRNA levels in U2OS cells transfected with siRNA-­‐CTRL, -­‐TIP5 and -­‐EZH2. Values of 45S
pre-­‐rRNA levels were first normalized to L28 mRNA levels and then to levels of siRNA-­‐CTRL transfected cells.
B | RT-­‐qPCR. ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 mRNA levels in U2OS cells transfected with siRNA-­‐CTRL,
-­‐TIP5 and -­‐EZH2. Values of EZH2-­‐target genes mRNA levels were first normalized to L28 mRNA levels and then
to levels of siRNA-­‐CTRL transfected cells.
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5.8 Analysis of EZH2-target genes in U2OS cells depleted of TIP5 and EZH2 
Given the known role of EZH2 in repressing transcription of ADRB2 and DAB2IP in prostate cancer 
cells and of CNR1, KCNA1 and MYT1 in U2OS cells (see 5.5), we asked whether TIP5 might be 
implicated in the transcriptional repression of these genes. To test this, we measured expression levels 
in U2OS cells depleted of TIP5 and EZH2 by siRNA. Surprisingly, and in contrast to a previous 
published report [71], knockdown of EZH2 did not affect the levels of CNR1, KCNA1 and MYT1 in 
U2OS cells. We repeated this analysis several times but we have never been able to obtain 
upregulation of these genes upon EZH2 depletion, despite the good knockdown efficiency and 
validation of the primers used to measure transcript levels. An important point for the interpretation 
of these results is that we have not been able to obtain sequence information of the primers used in 
Vire et al., 2006. Indeed, CNR1, KCNA1 and MYT1 have several transcript variants and there is the 
possibility that our primers measured other isoforms of MYT1 than the one described in Vire et al., 
2006. We conclude that the analyzed transcript variants of CNR1, KCNA1 and MYT1 are not 
transcriptionally regulated by EZH2 in U2OS cells. As expected, knockdown of TIP5 did not 
significantly affect transcript levels (Figure 9 B). 
Transcription of ADRB2 and DAB2IP was also not affected by TIP5 and EZH2 in U2OS (Figure 9 B), 
suggesting that these genes, known to be regulated by EZH2 in prostate cancer PC3 and DU145 cells 
[199, 201], are not regulated by EZH2 in U2OS osteosarcoma cell line. In my master thesis we 
reported a 1.4 fold increase in ADRB2 expression upon short-time (three days) EZH2 knockdown in 
PC3 cells while upregulation upon TIP5 knockdown could only be detected after long-time depletion 
(several weeks). Thus, we cannot exclude the possibility that upregulation of ADRB2 in U2OS cells 
might require longer exposure to EZH2 or TIP5 depletion to efficiently erase stable epigenetic marks 
such as DNA methylation required for transcription activation. Indeed, our DNA methylation array 
analysis in PC3 cells determined that 4 days of TIP5 or EZH2 knockdown were not sufficient to 
modify DNA methylation profile (data not shown). 
 
Taken together, the results indicated that depletion of EZH2 and TIP5 does not affect transcript levels 
of genes previously described by others to be regulated by EZH2 under our experimental conditions 
(primer choice and time of knockdown). 
 
5.9 TIP5 binds to EZH2-target genes in U2OS cells 
The analysis described above showed that 6 out of 9 selected RTEM genes (identified in PC3 cells) are 
transcriptionally regulated by TIP5 and EZH2 in U2OS cells, indicating that TIP5 and EZH2 regulate 
RTEM genes’ transcription not only in prostate cancer cells but also in osteosarcoma cells.  In contrast, 
we were unable to detect upregulation upon 4 days TIP5 or EZH2 knockdown of genes previously 
described to be EZH-targets in U2OS and prostate cancer cells. To get better insights into EZH2- and 
TIP5-regulation, we performed chromatin immunoprecipitation (ChIP) analyses to measure the 
association of TIP5 or EZH2 with the promoter regions of the candidate genes in U2OS cells. My 
previous results reported in my master thesis showed TIP5 enrichment at ADRB2 gene promoter in 
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HEK293T and PC3 cells and binding to DAB2IP and MYT1 promoter in PC3 cells. Further 
experiments (performed by Sandra Frommel, data not shown) revealed that TIP5 and EZH2 
associated with the promoter regions of all analysed RTEM genes in PC3 cells, supporting a direct 
role of TIP5 and EZH2 in the regulation of RTEM genes. As shown in Figure 10 A, anti-TIP5 ChIP 
assay in U2OS cells revealed the association of TIP5 with the rDNA promoter region but not with the 
rDNA coding region located at +4 kb from the TSS, a result consistent with previous data that 
underscores the specificity of this assay [81]. GAPDH and IL6 promoter, genes that are not related to 
TIP5 and EZH2, were used as additional controls to assess the specificity of the ChIP assay. In 
contrast to the transcription data presented in Figure 9 B, we found that TIP5 specifically associated 
with the promoter regions of ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 (Figure 10 A). Binding of 
EZH2 to these promoters was also enriched when compared to control genes GAPDH and IL6  
(Figure 10 B). These results suggest that ADRB2, DAB2IP, CNR1, KCNA1 and MYT1 are indeed 
EZH2- and TIP5-target genes in U2OS cells. The failure to detect transcriptional upregulation of 
theses genes upon TIP5 or EZH2 knockdown in U2OS cells (Figure 9 B) might have depended on our 
experimental condition (such as short time of knockdown) that is not sufficient to erase key 
epigenetic marks for transcriptional repression (i.e. DNA methylation). Alternatively, we cannot 
exclude the possibility of other factors that are still active in repressing transcription and do not 
depend on TIP5 or EZH2. 
 
5.10 Association of TIP5 and EZH2 with RTEM genes in U2OS cells 
Next, we wanted to determine whether RTEM genes in U2OS cells are directly regulated by TIP5 and 
EZH2 by measuring the association of TIP5 and EZH2. Studies performed by Sandra Frommel 
already determined that TIP5 and EZH2 associate with RTEM genes in PC3 cells (data not shown). 
Three of the selected RTEM genes could not be included in this analysis due to the lack of primers 
able to efficiently amplify the corresponding promoter regions (FBN1, HOMER2 and MKX). As 
shown in Figure 10 A, TIP5 binding was enriched at AOX1, HOXB8, KLF6 and LAMB3 while at the 
other genes the levels were similar to control GAPDH and IL6 promoters. Binding of EZH2 was 
enriched only at HOXB8, while all the other RTEM genes did not display any evident association with 
EZH2. Lack of TIP5 and EZH2 binding at HOXA7 and ZNF185 is consistent with our analysis 
showing the transcription of both genes does not depend on TIP5 and EZH2 in U2OS cells  
(Figure 8 B). The absence of TIP5 and EZH2 binding to RTEM genes whose transcription depends on 
TIP5 or EZH2 (Figure 8 B), suggest that the regulation might occur in an indirect way  
(i.e. downregulation or upregulation of an transcriptional activator or repressor of RTEM genes). 
Thus, although the majority of RTEM genes are regulated by TIP5 and EZH2 in both U2OS and PC3 
cells, the mechanisms underlying these processes might considerably be different. 
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Figure 10 | TIP5-­‐, EZH2-­‐, and TTF1-­‐target genes in U2OS cells
A | ChIP assay showing association of TIP5 with the indicated genes. Values are calculated bound/input and
then normalized to rDNA promoter binding. Error bars indicate SD of two independent experiments. B | ChIP
assay showing association of EZH2 with the indicated genes. Values are calculated bound/input and then
normalized to rDNA promoter binding. C | ChIP assay showing association of TTF1 with the indicated genes.
Values are calculated bound/input and then normalized to rDNA promoter binding. 
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5.11 Association of TTF1 with EZH2-target genes and RTEM genes in U2OS cells 
How is TIP5 recruited to EZH2-target genes (ADRB2, DAB2IP, CNR1, KCNA1 and MYT1) and RTEM 
genes (AOX1, HOXB8, KLF6 and LAMB3) in U2OS cells? 
TIP5 was identified with a two-hybrid screen with the transcription terminator factor 1 (TTF1) as bait 
[85]. TTF1 binds to terminator (T) elements, sequences that are located at the 5’- and 3’-rDNA 
sequences and is implicated in several rRNA regulatory processes such as transcript termination, 
replication fork arrest and transcription [217-219]. The binding of TTF1 to the T0 element at the rDNA 
promoter led to propose a role of TTF1 in the recruitment of TIP5 to rDNA [84, 220]. To determine 
whether TIP5 uses similar recruitment mechanisms as described for rRNA genes, we measured the 
association of TTF1 with selected genes by ChIP analysis. As shown in Figure 10 C, anti-TTF1 ChIP 
assay in U2OS cells revealed the association of TTF1 with the rDNA promoter region but not with the 
rDNA coding region located at +4 kb from the TSS, underscoring the specificity of this assay. Also in 
this analysis, GAPDH and IL6 promoter – genes that are not related to TTF1 – were used as 
additional controls to assess the specificity of the ChIP assay. All the EZH2-target genes in U2OS 
except MYT1 showed enrichment for TTF1 association. Of the RTEM genes, only KLF6 displayed an 
association with TTF1. 
Taken together, the results suggest that TTF1-mediated recruitment of TIP5 to rDNA might be a 
mechanism used also for other genes than rRNA genes. As TTF1 binds to DNA in a sequence 
dependent manner, future studies will aim to find the common DNA elements on the regulatory 
sequences of RTEM and EZH2-/TIP5-target genes. 
 
5.12 Association of TIP5 and EZH2 in PC3 cells 
Previous experiments of our laboratory showed an interaction of TIP5 and EZH2 when analyzed in 
HEK293T cells overexpressing tagged TIP5 and EZH2 (data not shown). To determine whether 
endogenous EZH2 associates with TIP5 in PC3 cells, we expressed HA-Flag-TIP5 and HA-Flag-TIP5-
700 (representing the first 700 amino acids of N-terminal TIP5) and performed co-
immunoprecipitation (Co-IP). 
Since PC3 cells are hard-to-transfect cells, we transduced the PC3 cells with retroviruses expressing 
HA-Flag-TIP5. Although the transducing efficiency was elevated (ca. 90% according to GFP 
expression of the control cells), HA-Flag-TIP5 expression levels were very low and we were not able 
to detect any signal from western blots of nuclear extracts and anti-Flag immune-precipitates. Since 
previous experiments determined that PC3 cells are not efficiently transfected using calcium 
phosphate and electroporation methods, we tested some commercial transfection kits. We found that 
X-tremeGENE HP DNA transfection kit from Roche had the best transfection efficiency in PC3 and 
the expression of TIP5 could be detected on western blot of nuclear extracts (Input sample of  
Figure 11). As expected, expression and IP of HA-TIP5-700 were more efficient than with full length 
TIP5 and we were able to detect co-immunoprecipitation of known TIP5-interacting proteins such as 
SNF2H and PARP1 [85, 221] but not EZH2 (Figure 11). Unfortunately, HA-Flag-TIP5 full-length 
expression was still low and, although it could be immune-precipitated, we detected the association 
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of the very strong interacting protein SNF2H that is part of NoRC complex, but not of PARP1. 
Similarly, we were not able to identify EZH2 as TIP5-associated protein (Figure 11). Thus, these 
results cannot be considered conclusive in determining whether TIP5 associates with EZH2 but 
provides important technical information for the identification of TIP5-interacting proteins in PC3 
cells that is currently under study in the laboratory of Dr. Santoro. 
 
 
Figure 11 | No association of TIP5 and EZH2 detectable in PC3 cells
Western blots showing FLAG-­‐immunoprecipitation from PC3 cells expressing HA-­‐FLAG-­‐TIP5 or
HA-­‐FLAG-­‐TIP5-­‐700. PC3 cells were transfected with GFP-­‐C1, HA-­‐FLAG-­‐TIP5 (RS58F) or HA-­‐FLAG-­‐TIP5-­‐700
(RS322) using the X-­‐tremeGENE HP DNA transfection reagent from Roche.
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6 Discussion 
Cancer evolution at all stages is driven by an alliance of genetic alterations and epigenetic 
abnormalities. Epigenetic alterations such as CpG hypermethylation of promoters and histone 
modifications are common phenomena observed in almost all human tumors and contribute to cancer 
pathogenesis [222, 223]. Altered expression and/or mutation of epigenetic regulators that have roles 
as 'writers', 'readers' or 'editors' of DNA methylation, histone modifications and/or functions in 
chromatin remodeling are common features of tumor cells and have the potential to deregulate genes 
critical to cancer [224-226]. These alterations may be used to further stratify tumors into subtypes of 
different histopathological groups or clinical outcomes as exemplified by cancer-specific methylation 
patterns in selected gene promoter sequences [225, 227-229]. 
Prostate cancer is the most common non-cutaneous malignancy in men. Despite intensive research, 
the prediction of clinical behavior remains challenging using the currently available histopathological 
and biochemical (prostate-specific antigen, PSA) markers, thus novel molecular-based approaches 
will likely improve prognostic accuracy in the disease. In addition, rationally designed therapies 
directed at molecular targets beyond the androgen receptor pathway have yet to show clinical impact. 
Since prostate cancer is characterized by a low frequency of mutations [230], aberrant gene activity 
contributing to prostate cancer is likely based on alterations in gene expression levels, which can be 
driven by copy number alterations and/or translocations (such as PTEN, TP53 loss and ERG fusions) 
or by alterations in transcriptional or post-transcriptional regulation. 
 
The results of my master and doctoral theses started to define an important role of TIP5 in prostate 
cancer. TIP5 is overexpressed in metastatic prostate tumors and coordinates with EZH2 epigenetic 
silencing at genes that are frequently repressed in metastatic and aggressive prostate cancer. Further 
work performed by Sandra Frommel, PhD student in the laboratory of Dr. Santoro, and in 
collaboration with the laboratories of Prof. C. Plass (DKFZ, Heidelberg), Prof. R. Eils (DKFZ, 
Heidelberg) and Prof. G. Sauter (University of Hamburg) defined that 1) TIP5 is necessary for 
proliferation, viability, migration and invasion of prostate cancer cells and that 2) TIP5 level is an 
independent prognostic marker of recurrence, especially in low/intermediate risk cases as assessed 
by Gleason score. Intermediate risk cases are a patient sub-cohort where most uncertainty exists to 
balance between active surveillance or immediate definite therapy in order to avoid overtreatment. 
Thus, screening of TIP5 levels in biopsies may be a valuable biomarker to distinguish prostate cancer 
that possesses the potential for disease progression, aiding in therapy decision making this important 
patient subgroup. The results of this work were recently published online ahead of print in Nature 
Genetics (“BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its 
overexpression predicts disease recurrence” Lei Gu, Sandra C. Frommel, Christopher C. Oakes, 
Ronald Simon, Katharina Grupp, Cristina Y. Gerig, Dominik Bär, Mark D. Robinson, Constance Baer, 
Melanie Weiss, Zuguang Gu, Ruprecht Kuner, Holger Sültmann, Maurizio Provenzano, ICGC Project 
on Early Onset Prostate Cancer, Marie-Laure Yaspo, Benedikt Brors, Jan Korbel, Thorsten Schlomm, 
Guido Sauter, Roland Eils, Christoph Plass and Raffaella Santoro; doi:10.1038/ng.3165). 
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The results presented here also might have important therapeutic implications. Lethality in prostate 
cancer is linked to the evolution of a metastatic phenotype. PSA recurrence following radical 
prostatectomy reveals that tumor cells have gained the ability to invade the surrounding local tissues 
and/or metastasize prior to surgery. We showed a key role for TIP5 in the regulation of genes related 
to metastatic features (this work) and in the growth and invasiveness of metastatic prostate cancer 
cells. Our results suggest that high TIP5 levels in the primary tumor indicate a higher probability of 
metastasis, linking molecular findings with recurrence in clinical samples. TIP5 may be involved in 
endowing cells with these abilities and could represent a promising therapeutic target for metastatic 
prostate cancer. An increasing number of epigenetic regulatory genes, including members of the class 
bromodomain-containing proteins, are currently found to be dysregulated across many cancer types 
[231]. These genes represent novel targets of a new generation of potential cancer therapeutics. In line 
with this, the fact that TIP5 contains a bromodomain previously shown to be important for its 
silencing function at the rDNA locus [232], might open the possibility to develop compounds to 
inactivate TIP5 function in cancer. 
 
The identification of genes regulated by TIP5 and EZH2 described in this work underscores a tight 
link between TIP5 and EZH2. Not only we determined that in PC3 cells about one third of genes 
regulated by TIP5 are also targets of EZH2 and vice versa but also that TIP5- and EZH2-regulated 
genes are implicated in common biological processes. We discovered two distinct processes. Genes 
downregulated by TIP5 or EZH2 are involved in immune-response process while upregulated genes 
belong to developmental functions. Although these genes downregulated upon TIP5 and EZH2 
knockdown are likely not direct targets it is to note that this pathways have been previously 
implicated in prostate cancer. For example, STAT1, a gene downregulated upon TIP5 knockdown, 
has been recently identified as a proto-oncogene product in a variety of cancers, including metastatic 
prostate cancer [233]. The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L) also known as B-
lymphoma and BAL-associated protein (BBAP) was originally identified as a binding parter of 
PARP9 [234, 235]. Both DTX3L and PARP9 are downregulated upon TIP5 knockdown in PC3 cells 
(this work). DTX3L is overexpressed in subtypes of high-risk chemotherapy-resistant aggressive HR-
DLBCL with an active host inflammatory response and tightly associated with intrinsic IFNγ 
signaling and constitutive activity of STAT1 [235, 236]. Finally, STAT1, DTX3L and PARP9 have been 
recently described to mediate proliferation and survival of metastatic prostate cancer cells [237]. 
Future studies will aim to define how TIP5 and EZH2 contribute to these pathways.  
The fact that genes upregulated upon TIP5 and EZH2 knockdown are implicated in developmental 
process suggest an important link with stem cell features. Recently developed system biology 
approaches have revealed highly interconnected networks in which multiple regulatory factors act in 
combination. Interestingly, stem cells and cancer cells share some properties, notably self-renewal 
and a block in differentiation. Of note is that the expression signatures that are specific to embryonic 
stem cells (ESCs) are also found in many human cancers and in mouse cancer models, suggesting that 
these shared features might inform new approaches for cancer therapy. Interestingly, analysis of TIP5 
in mouse ESCs revealed a regulation similar to that found in PC3 cells. Knockdown of TIP5 slowed 
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down proliferation of ESCs and upregulated transcription of genes implicated in development, 
particularly Hox genes as found in PC3 cells. 
This work also explored the possibility that TIP5 is implicated in epigenetic regulation in other cancer 
than prostate such as osteosarcoma. In U2Os cells 6 out of 9 analyzed RTEM genes showed enhanced 
transcription following knockdown of TIP5 and EZH2 indicating that the role of TIP5 and EZH2 to 
regulate RTEM genes’ transcription is not limited to prostate cancer, but is also true in osteosarcoma 
cells. The ChIP analyzes in U2OS cells revealed binding of TIP5 and EZH2 only at a few primes of 
RTEM genes (Figure 8 A and B) although transcription analyzes determined a transcriptional state 
mediated by TIP5 or EZH2. The absence of TIP5 and EZH2 binding to RTEM gene promoters whose 
transcription depends on TIP5 or EZH2 suggests that the regulation in U2OS cells might occur in an 
indirect way, for instance through downregulation of a transcriptional activator or upregulation of a 
transcriptional repressor of RTEM genes. 
 
An important question of this study was to define how TIP5 is recruited to RTEM genes. The first 
genes described to be regulated by TIP5 was the ribosomal RNA gene [81]. TTF1 is the “docking” 
protein that binds to rDNA promoter in a sequence specific manner and associates with TIP5. We 
found that ca. 50% of the analyzed TIP5-target genes in U2OS associate with TTF1 suggesting that 
TIP5 recruitment might share similar mechanisms to that one found for rRNA genes. ChIPseq 
analyzes of TIP5 and TTF1 in PC3 cells (currently performed in Santoro’s lab) will unravel important 
insights on the mechanisms for TIP5 binding and regulation in PC3 cells. 
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7 Abbreviations 
acetyl-CoA Acetyl coenzyme A 
ADP Adenosine diphosphate 
ADRB2 Adrenoceptor beta-2, surface 
ALL Acute lymphoblastic leukemia 
AO Aldehyde oxidase 
AOX1 Aldehyde oxidase 1 
ATEM Activated by TIP5 and EZH2 in metastasis 
ATP Adenosine triphosphate 
BBAP B-lymphoma- and BAL-associated protein 
BMI-1 B lymphoma Mo-MLV insertion region 1 homolog 
bp Base pair(s) 
CBX Chromobox homolog 
cDNA Complementary DNA 
ChIP Chromatin immunoprecipitation 
ChIPseq Chromatin immunoprecipitation sequencing 
cm Centimeter 
CNR1 Cannaboid receptor 1 (brain) 
CNS Central nervous system 
CoIP Co-immunoprecipitation 
CpG Cytosine-phosphate-Guanine 
Ct Cycle threshold 
CTRL Control 
DAB2IP Disabled homolog 2-interacting protein 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
DNMT DNA methyltransferase 
dNTP Deoxynucleotide triphosphates 
DOT1L DOT1-like protein 
DTX Deltex 
DTX3L Deltex-3-like E3 ubiquitin ligase 
EDTA Ethylenediaminetetraacetic acid 
EED Embryonic ectoderm development 
ERG V-ets avian erythroblastosis virus E26 oncogene homolog 
ESCs Embryonic stem cells 
EtOH Ethanol 
ETV E-twenty six translocation variant 
EZH2 Enhancer of zeste homolog 2 
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FAS Tumor necrosis factor receptor superfamily member 6 
FBN1 Fibrillin 1 
FHL2 Four and a half LIM domains 2 
g Earth’s gravitational acceleration 
GAP GTPase-activation protein 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GDS GEO data set 
GEO Gene expression omnibus 
GFP Green fluorescent protein 
GO Gene ontology 
h Hour 
HA Haemagglutinin 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HMT Histone methyltransferase 
HOMER2 Homer homolog 2 (Drosophila) 
HOXA7 Homeobox A7 
HOXB8 Homeobox B8 
HP1 Heterochromatin protein 1 
IGS Intergenic spacer sequence 
IL6 Interleukin 6 
IP Immunoprecipitation 
K Lysine 
KCNA1 Potassium voltage-gated channel, shaker-related subfamily, member 1 
KLF Krüppel-like factor 6 
K-ras Kirsten rat sarcoma viral oncogene homolog 
kb Kilobases 
kDa Kilodalton 
L28 Ribosomal protein L28 
LAMB3 Laminin, beta 3 
M Molar 
MBD Methyl-CpG-binding domain 
me Methylation 
mg Milligram 
min Minute 
miRNA Micro RNA 
MKX Mohawk homeobox 
ml Milliliter 
MLL Myeloid-lymphoid leukaemia 
mM Millimolar 
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mRNA Messenger RNA 
MuLV Murine leukemia virus 
MYC V-Myc avian myelocytomatosis viral oncogene homolog 
MYO18B Myosin XVIIIB 
MYT1 Myelin transcription factor 1 
ng Nanogram 
nl Nanoliter 
nm Nanometer 
NOR Nucleolar organizing region 
NoRC Nucleolar remodeling complex 
nts Nontranscribed spacer 
OD Optical density 
PARP Poly(ADP-ribose) polymerase 
PARP1 Poly(ADP-ribose) polymerase 1 
PARP9 Poly(ADP-ribose) polymerase family, member 9 
PB Polybrene 
PBS Phosphate buffered saline 
PCa Prostate cancer 
PcG Polycomb group 
PCGF Polycomb group ring finger 
PHC Polyhomeotic-like 
PI Protease inhibitor 
PLAGL1 Pleiomorphic adenoma gene-like 1 
PKr Prostatakrebs 
Pol I RNA polymerase I 
PRC1 Polycomb repressive complex 1 
PRC2 Polycomb repessive complex 2 
pRNA Promoter RNA 
PSA Prostate-specific antigen 
PTEN Phosphatase and tensin homolog 
qPCR Quantitative polymerase chain reaction 
RAS Rat sarcoma protein 
RbAp46/48 Retinoblastoma-binding protein 46/48 
rDNA Ribosomal DNA 
RESEs Ras epigenetic silencing effectors 
RING1 Really interesting new gene 1 
RNA Ribonucleic acid 
rpm Rounds per minute 
RTEM Repressed by TIP5 and EZH2 in metastasis 
rRNA Ribosomal RNA 
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RT Reverse transcriptase 
RT-qPCR Reverse transcription quantitative polymerase chain reaction 
s Second 
S-phase Synthesis phase 
SAM S-Adenosyl methionine 
SCML Sex comb on midleg-like 
SD Standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFRP1 Secreted frizzled-related protein 1 
siRNA Small interfering RNA 
SL1 Selectivity factor 1 
SMARCA5 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 5 
SMYD1 SET and MYND domain-containing protein 1 
SNF2H Sucrose non-fermenting protein 2 homolog 
STAT1 Signal transducer and activator of transcription 1 
SUZ12 Suppressor of zeste 12 protein homolog 
T Terminator 
THAP2 THAP domain containing, apoptosis associated protein 2 
THC Tetrahydrocannabinol 
TIF-IA Transcription initiation factor IA 
TIP5 Transcription termination factor I-interacting protein 5 
TP53 Tumor protein 53 
TSS Transcription start site 
TTF1 Transcription termination factor, RNA polymerase I 
UBF Upstream binding factor 
V Volt 
Y Tyorsine 
ZNF185 Zinc finger protein 185 (LIM domain) 
°C Degree Celsius 
μg Microgram 
μl Microliter 
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